The University of Chicago Header Logo

Wendy Stock

TitleProfessor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
Email
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Stock W, Cassaday RD, DeAngelo DJ, Advani A, Gokbuget N, Ribera J, Jiang W, Pulido S, Vandendries E, Braniff N, Jabbour E, Kantarjian H. Outcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin. Target Oncol. 2026 Sep 16. PMID: 42747695.
      Citations:    
    2. Yates SJ, Terman E, Miller L, Cursio JF, Wild C, Huisingh-Scheetz M, Zhang M, Feinberg N, Popuri K, Beg MF, Akella V, Youshanlouei H, Noorani A, Mathews J, Saygin C, Patel AA, Odenike O, Larson RA, Nawas MT, Stock W. Association of sarcopenia with treatment tolerance in older adults with acute myeloid leukemia using artificial intelligence computed tomography-segmentation and a geriatric assessment. Leukemia. 2026 Aug 31. PMID: 42675142.
      Citations:    
    3. Silva WF, Yin J, Liedtke M, Claxton DF, Fulton N, Giri S, Malnassy G, Mrózek K, Paietta E, Mullighan CG, Galinsky I, Bogart JA, Grecula JC, Kennedy L, Larson RA, Stone RM, Uy GL, Luger SM, Advani AS, Stock W. Long-term follow-up of a pediatric regimen for AYA with Ph-negative ALL: 10-year survival of CALGB 10403 (alliance). Blood Adv. 2026 Aug 25; 10(16):5487-5491. PMID: 42101912; PMCID: PMC13486816.
      Citations:    Fields:    
    4. Muffly L, Frey NV, Roloff GW, Park JA, Dholaria B, Advani A, Bachanova V, Cassaday RD, Daunov M, Dykes KC, Gatell VI, Grunwald MR, Hilal T, Hill LC, Jamy O, Kota VK, Kumaran MV, Lin C, Logan AC, Luskin MR, O'Dwyer KM, Oliai C, Oluwole OO, Sasine JP, Schwartz MS, Solh MM, Stock W, Tsai SB, Ulrickson M, Vasu S, Wang ES, Yalniz FF, Strickland SA, Leonard JT, Shah BD, Aldoss I. Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study. Blood. 2026 08 06; 148(6):657-668. PMID: 42154904.
      Citations:    Fields:    Translation:Humans
    5. Shimamoto K, Karaoglu DA, Arnold O, Dhar A, Chan Z, Giordano G, Cheng JX, Youshanlouei HR, Patel AA, DuVall AS, Drazer MW, Kessler L, Burrows F, Odenike O, Thirman MJ, Stock W, Saygin C, Shimamoto K, Karaoglu DA, Arnold O, Dhar A, Chan Z, Giordano G, Cheng JX, Youshanlouei HR, Patel AA, DuVall AS, Drazer MW, Kessler L, Burrows F, Odenike O, Thirman MJ, Stock W, Saygin C. Targeting Menin in T-lineage Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2026 Aug 04; 25(8):1294-1304. PMID: 41778833; PMCID: PMC13434301.
      Citations:    Fields:    Translation:HumansAnimalsCells
    6. Borate UM, Huang Y, Lin TL, Handa S, Swords R, Lachowiez CA, Traer E, Stock W, Odenike O, Patel AA, Baer MR, Duong VH, Stein EM, Blum W, Vale CA, Curran E, Madanat YF, Olin RL, Schiller GJ, Nichols AD, Williams L, Heerema NA, Johnson MF, Chen TL, Marcus S, Martycz M, Stefanos M, Rosenberg L, DeGennaro LJ, Gruenbaum L, Burd A, Byrd JC, Druker BJ, Levine RL, Yocum AO, Mims AS, Zeidner JF. OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML. Blood. 2026 Jul 28. PMID: 42520193.
      Citations:    Fields:    
    7. Grimes AC, Wolfson JA, Kerber CL, Bingen KM, Beauchemin MP, Boayue KB, Levine JM, Scialla MA, Woods WL, Liu JJ, Ponce O, Vargas SL, Advani AS, Chang GJ, Curran EK, Hershman DL, Luger SM, O'Dwyer KM, Stock W, Dickens DS, Roth ME, Freyer DR, Pollock BH, Sung L, Parsons SK. Adolescents and Young Adults With Acute Lymphoblastic Leukemia: Qualitative Barriers and Facilitators to Guideline-Concordant Care. Cancer Control. 2026 Jan-Dec; 33:10732748261469238. PMID: 42474359; PMCID: PMC13385608.
      Citations:    Fields:    Translation:Humans
    8. Yoshimura S, Li Y, Inoue S, Meyer CT, Yang X, Du G, Hsiao YC, Li Z, Yang W, Hu J, Andersen CL, Saygin C, Karol SE, Bernt KM, Yu J, Stock W, Teachey DT, Konopleva M, Yang JJ. Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2026 Jul 17; 32(14):3018-3030. PMID: 41995729; PMCID: PMC13198711.
      Citations:    Fields:    Translation:HumansAnimalsCells
    9. DuVall AS, McNeer J, Cheung MC, Adrianzen-Herrera DA, Advani A, Aljurf M, Audino A, Benitez L, Deeter A, Dworkin E, Hiltbrand O, Isenalumhe L, Li L, Miller-Chism C, Mozessohn L, Ng AP, Pu JJ, Shafer D, Madueno FV, Viny A, Wadhwa A, Yang J, Zarnegar-Lumley S, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Stock W, Wolfson JA. American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults. Blood Adv. 2026 Jul 14; 10(13):4671-4708. PMID: 41670627; PMCID: PMC13366240.
      Citations:    Fields:    Translation:Humans
    10. Hoff FW, Zeidner JF, Torlapati G, Nicolet D, Mrózek K, Huang Y, Li A, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Olin RL, Smith CC, Schiller GJ, Curran EK, Chan O, McMahon C, Hochman M, Sahasrabudhe K, Foucar C, Gonzalez-Lugo J, Knick Ragon B, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Eisfeld AK, Byrd JC, Madanat YF. Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA. Am J Hematol. 2026 Sep; 101(9):2246-2257. PMID: 42393840; PMCID: PMC13428408.
      Citations:    Fields:    Translation:HumansCells
    11. Lee D, Abu-Shihab Y, Plas K, Nicolet D, Mrózek K, Routbort MJ, Patel KP, Walker CJ, Buss J, Stiff AR, Laganson A, DiNardo CD, Daver NG, Kadia TM, Ravandi F, Carroll AJ, Kolitz JE, Powell BL, Blum WG, Baer MR, Marcucci G, Uy GL, Stock W, Stone RM, Medeiros LJ, Byrd JC, Blachly JS, Bowman RL, Tyner JW, Loghavi S, Eisfeld AK, Miles LA. Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia. Leukemia. 2026 Aug; 40(8):1688-1697. PMID: 42297916; PMCID: PMC13421326.
      Citations:    Fields:    Translation:Humans
    12. Sereda Y, Mai HJ, Kanaan G, Melson JW, Terasawa T, Cheung MC, Stock W, Wolfson JA, Saldanha IJ, Balk EM. Pediatric-inspired regimens and HSCT for adolescents and young adults with acute lymphoblastic leukemia. Blood Adv. 2026 May 26; 10(10):3664-3675. PMID: 41610329; PMCID: PMC13207624.
      Citations:    Fields:    Translation:Humans
    13. Ranasinghe D, Lin WY, Fordham SE, Alharbi A, Sunter NJ, Elstob C, Nahari MH, Xu Y, Park C, Hungate E, Quante A, Strauch K, Gieger C, Skol A, Rahman T, Sucheston-Campbell L, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Enshaei A, Gunasinghe D, Hawking ZL, Heslop H, Nandana D, Di B, Plokhuta A, Brown IT, Allsup DJ, Houlston RS, Collins A, Milne P, Norden J, Dickinson AM, Lendrem C, Daly AK, Palm L, Piechocki K, Jeffries S, Bornhäuser M, Röllig C, Altmann H, Ruhnke L, Kunadt D, Wagenführ L, Cordell HJ, Darlay R, Andersen MK, Fontana MC, Martinelli G, Marconi G, Sanz MA, Cervera J, Gómez-Seguí I, Cluzeau T, Moreilhon C, Raynaud S, Sill H, Voso MT, Dombret H, Cheok M, Preudhomme C, Gale RE, Linch D, Weisinger J, Masszi A, Nowak D, Hofmann WK, Gilkes A, Porkka K, Milosevic Feenstra JD, Kralovics R, Wang J, Meggendorfer M, Haferlach T, Krizsán S, Bödör C, Parkin B, Malek SN, Stölzel F, Onel K, Allan JM. Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia. Blood. 2026 04 23; 147(17):1958-1969. PMID: 41610418.
      Citations: 1     Fields:    Translation:HumansCells
    14. Srinagesh HK, Gupta V, Zhang A, Grunwald M, Connor M, Kota VK, Boccucci J, Ulrickson M, Pradeep R, Hill L, Tsai SB, O'Connor T, Sandhu K, Advani AS, Reshef R, Gordillo CA, Luskin MR, Chen EC, Lin C, Cassaday RD, Kopmar NE, Majhail NS, Battiwalla M, Strickland SA, Lee CJ, Bobillo SO, Hilal T, Park JH, Valtis YK, Faramand R, Solh MM, Guzowski C, Vasu S, Leonard JT, Tan V, Wang ES, McCauley R, Sasine J, Tang K, Miller K, Sutherland KC, Daunov M, Mohty R, Jamy O, Kumaran MV, Hoeg RT, Dykes KC, Logan AC, Othman T, Stock W, Schwartz M, Byrd K, Yalniz F, Bachanova V, Tracy S, Yaghmour G, Irizarry Gatell VM, Jackson CW, Oluwole OO, Dholaria B, O'Dwyer KM, Moore J, Roloff GW, Frey NV, Aldoss I, Shah BD, Oliai CH, Muffly LS. Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL. Blood. 2026 04 23; 147(17):2011-2017. PMID: 41643192.
      Citations:    Fields:    Translation:Humans
    15. Hochman MJ, Ruppert AS, Huang Y, Mims A, Borate U, Swords R, Traer E, Baer MR, Duong VH, Stock W, Odenike T, Patel P, Madanat Y, Stein E, Deininger MW, Schiller G, Pollyea DA, Foran JM, Olin R, Lin T, Boyiadzis MM, Handa S, Rueter B, Gana TJ, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus S, Rosenberg L, Druker B, Levine R, Burd A, Yocum AO, Byrd JC, Blum W. Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results. Haematologica. 2026 Apr 23. PMID: 42021690.
      Citations:    Fields:    
    16. Zeidner JF, Jain J, Welkie RL, Huang Y, Swords RT, Traer E, Stein EM, Lin TL, Madanat YF, Collins RH, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran EK, Handa S, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Mims AS, Byrd JC, Borate U. Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report. Blood Adv. 2026 Apr 14; 10(7):2328-2332. PMID: 41632633; PMCID: PMC13066953.
      Citations:    Fields:    
    17. Saldanha IJ, Sereda Y, Kanaan G, Mai HJ, Melson JW, Terasawa T, Gupta S, O'Dwyer KM, Wolfson JA, Stock W, Cheung MC, Balk EM. Prioritized health outcomes for adolescents and young adults with acute lymphoblastic leukemia. Blood Neoplasia. 2026 May; 3(2):100222. PMID: 42095126; PMCID: PMC13141049.
      Citations:    Translation:CTClinical Trials
    18. Anderson DR, Gangaraju R, Sedhom WG, Hamulyák EN, Wang TF, O'Dwyer K, Carney BJ, Muthiah C, Liedtke M, Badar T, Shimony S, Robinson R, Sanfilippo K, Derkach A, Dinner S, Biemond BJ, Nemirovsky D, Goldberg LA, Kapadia AD, Levavi H, Bar-Natan M, Van Hyfte G, Bansal K, Carrier M, Fulcher J, Gerrits AM, Litzow MR, Luger S, Guru Murthy GS, Luskin M, Wolach O, Shomali W, Zwicker JI, Stock W, Leader A. Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL. Blood Adv. 2026 Feb 10; 10(3):593-603. PMID: 41170879.
      Citations:    Fields:    Translation:Humans
    19. Hantel A, Wang Y, Cronin A, Khan I, Abraham IE, Eisfeld AK, Patel AA, Stock WA, Monick S, Walsh TP, Gallagher E, Luskin MR, Avila Rodriguez AM, Galvez C, Doukas PG, Altman JK, Burkart M, Erra A, Zia M, Larson ML, Dave A, Tsai SB, Aleem A, Raptis NI, Lathan CS, Uno H, DeAngelo DJ, Abel GA, Hantel A, Wang Y, Cronin A, Khan I, Abraham I, Eisfeld AK, Patel AA, Stock W, Monick S, Walsh TP, Gallagher E, Luskin MR, Avila Rodriguez AM, Galvez C, Doukas P, Altman JK, Burkart M, Erra A, Zia M, Larson ML, Dave A, Tsai SB, Aleen A, Raptis N, Lathan CS, Uno H, DeAngelo DJ, Abel GA. Impact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials. Blood. 2026 Feb 05; 147(6):639-649. PMID: 41100728; PMCID: PMC13000933.
      Citations:    Fields:    Translation:Humans
    20. Cannova JM, Battaglia MR, Roloff GW, Cetin S, Tallarico M, Stock W, Patel AA, Odenike O, Larson RA, Thirman MJ, Nawas MT, Wang P, Tjota MY, Segal JP, Venkataraman G, DuVall AS, Drazer MW. Hematologic complications in patients exposed to poly- ADP ribose polymerase inhibitors. Haematologica. 2026 Jul 01; 111(7):2451-2456. PMID: 41609051; PMCID: PMC13317881.
      Citations:    Fields:    
    21. Abraham IE, Rauscher GH, Luo J, Monick S, Burkart M, Doukas P, Aleem A, Raptis N, Dave A, Wilmington A, Debettencourt M, Nwachukwu M, Fatima J, Erra A, Shankar G, Tsai SB, Larson M, Zia M, Quigley J, Altman JK, Stock W, Patel A, Khan I. Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemia. Haematologica. 2026 Jul 01; 111(7):2466-2471. PMID: 41537345; PMCID: PMC13317841.
      Citations:    Fields:    
    22. Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Zeidner JF, Olin RL, Smith CC, Schiller GJ, Curran EK, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF. IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy. Haematologica. 2026 05 01; 111(5):1625-1633. PMID: 41195510; PMCID: PMC13136839.
      Citations:    Fields:    Translation:HumansCells
    23. Thomas M, Johnston H, Dworkin E, Wesevich A, Roloff GW, Saygin C, Nawas MT, Drazer MW, DuVall AS, Kosuri S, Thirman MJ, Odenike O, Stock W, Larson RA, Madero-Marroquin R, Patel AA. Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies. Br J Haematol. 2026 Jan; 208(1):343-347. PMID: 41139955; PMCID: PMC12819088.
      Citations: 1     Fields:    
    24. Monick SE, Hanson C, Hoehn KS, Hlubocky FJ, Stock W, Duvall A, McNeer J, Henderson T, Daugherty C, Wang AY. Feasibility of Symptom Burden Assessments and Early Palliative Care Integration in an Adolescent and Young Adult Leukemia Clinic. J Adolesc Young Adult Oncol. 2026 Oct; 15(5):378-383. PMID: 41122915.
      Citations:    Fields:    
    25. Lee D, Abu-Shihab Y, Plas K, Nicolet D, Mrozek K, Routbort MJ, Patel KP, Walker CJ, Buss J, Stiff AR, Laganson A, DiNardo CD, Daver NG, Kadia TM, Ravandi F, Carroll AJ, Kolitz JE, Powell BL, Blum WG, Baer MR, Marcucci G, Uy GL, Stock W, Stone RM, Medeiros LJ, Byrd JC, Blachly JS, Bowman RL, Tyner JW, Loghavi S, Eisfeld AK, Miles LA. Prognostic and Therapeutic Implications of BRAF Mutations in Acute Myeloid Leukemia. bioRxiv. 2025 Oct 15. PMID: 41279970; PMCID: PMC12632951.
      Citations:    
    26. Palmer A, Rauscher G, Schoen A, Burkart M, Dunton A, Au C, Dave A, Nassar A, Zhu S, O'Hara A, Africawala N, Erra A, Solipuram V, Abraham I, Tsai SB, Zia M, Larson ML, Rondelli D, Altman JK, Stock W, Khan I, Odenike O, Patel AA. Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosis. Blood Cancer J. 2025 Oct 06; 15(1):158. PMID: 41053057; PMCID: PMC12501014.
      Citations:    Fields:    
    27. Wieduwilt MJ, Yin J, Kour O, Teske R, Stock W, Escherich C, Yang J, Li Z, Byrd K, Doucette K, Mangan J, Hall S, Mims AS, Jamieson K, Dinner SN, Bseiso AW, Giordano G, Saygin C, Uy GL, Litzow MR, Stone RM. Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results. J Clin Oncol. 2025 11 10; 43(32):3526-3535. PMID: 41026957; PMCID: PMC13093227.
      Citations: 5     Fields:    Translation:Humans
    28. Glaviano A, Weisberg E, Lam HY, Tan DJJ, Innes AJ, Ge Y, Lai CE, Stock W, Glytsou C, Smit L, Yoshida T, Zhang TY, Kennedy VE, Smith BD, Mercher T, de Botton S, Diana P, Konopleva M, Mauro MJ, Griffin JD, DiNardo CD, Kumar AP. Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia. Nat Rev Clin Oncol. 2025 Nov; 22(11):847-868. PMID: 40890352.
      Citations: 3     Fields:    Translation:Humans
    29. O'Connor TE, Lin C, Roloff GW, Zhang A, Miller K, Aldoss I, Kopmar NE, Dekker SE, Gupta VK, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Connor MP, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Blunk B, Logan AC, Ladha A, Advani AS, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, O'Dwyer KM, Hill LC, Sasine J, Oliai C, Solh MM, Lee CJ, Kota VK, Koura D, Kumaran MV, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Bishop MR, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly LS, Tsai SB, Dholaria B. The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Bone Marrow Transplant. 2025 11; 60(11):1465-1471. PMID: 40849364; PMCID: PMC12583187.
      Citations:    Fields:    Translation:Humans
    30. Harris EJ, Karaoglu DA, Sukhanova M, Abaza Y, Karantanos T, Eisfeld AK, Anderson C, Lin C, Moreno Vanegas YA, Badar T, Coltoff A, Knepper TC, Ozkaya N, Youshanlouei HR, Cetin S, Patel AA, DuVall AS, Drazer MW, Wang P, Tjota M, Segal JP, Venkataraman G, Gurbuxani S, Cheng JX, Arber DA, Larson RA, Odenike O, Webster J, Shah B, Stock W, Saygin C. Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 08 14; 15(1):138. PMID: 40813576; PMCID: PMC12354737.
      Citations: 4     Fields:    Translation:Humans
    31. Escherich CS, Li Z, Barnett KR, Li Y, Walker M, Yoshimura S, Yang W, Huang X, Yu J, Stock W, Paietta E, Konopleva MY, Kornblau SM, Jabbour E, Litzow MR, Inaba H, Pui CH, Loh ML, Evans WE, Savic D, Yang JJ, Escherich CS, Li Z, Barnett KR, Li Y, Walker M, Yoshimura S, Yang W, Huang X, Yu J, Stock W, Paietta E, Konopleva MY, Kornblau SM, Jabbour E, Litzow MR, Inaba H, Pui CH, Loh ML, Evans WE, Savic D, Yang JJ. Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin. Blood. 2025 Jul 24; 146(4):471-481. PMID: 40435412.
      Citations: 2     Fields:    Translation:HumansCells
    32. Iacobucci I, Zeng AGX, Gao Q, Garcia-Prat L, Baviskar P, Shah S, Murison A, Voisin V, Chan-Seng-Yue M, Cheng C, Qu C, Bailey C, Lear M, Witkowski MT, Zhou X, Zaldivar Peraza A, Gangwani K, Advani AS, Luger SM, Litzow MR, Rowe JM, Paietta EM, Stock W, Dick JE, Mullighan CG. Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features. Nat Cancer. 2025 Jul; 6(7):1242-1262. PMID: 40579588; PMCID: PMC12377259.
      Citations: 10     Fields:    Translation:HumansCells
    33. Madero-Marroquin R, Cannova J, Dworkin E, Wesevich A, Roloff GW, Saygin C, Nawas MT, DuVall AS, Kosuri S, Thirman MJ, Odenike O, Stock W, Larson RA, Drazer MW, Patel AA. Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. EJHaem. 2025 Jun; 6(3):e70078. PMID: 40521395; PMCID: PMC12163342.
      Citations:    
    34. Zeidner JF, Lin TL, Welkie RL, Curran E, Koenig K, Stock W, Madanat YF, Swords R, Baer MR, Blum W, Stein EM, Olin RL, Schiller G, Nichols A, Odenike O, Traer E, Lachowiez C, Duong VH, Hochman MJ, Cai SF, Smith C, Stefanos M, Martycz M, Huang Y, Rosenberg L, Marcus S, Chen TL, Yocum AO, Druker BJ, Levine RL, Borate U, Byrd JC, Mims AS. Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. J Clin Oncol. 2025 08 10; 43(23):2606-2615. PMID: 40504618; PMCID: PMC12316144.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    35. Marrero RJ, Shastri VM, Nicolet D, Mrózek K, Walker CJ, Blum WG, Powell BL, Kolitz JE, Moore JO, Uy GL, Stock W, Carroll AJ, Byrd JC, Aplenc R, Cooper TM, Gamis AS, Wu H, Pounds S, Wang YC, Alonzo TA, Meshinchi S, Eisfeld AK, Kolb EA, Lamba JK. Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia. JAMA Netw Open. 2025 06 02; 8(6):e2516296. PMID: 40549387; PMCID: PMC12186577.
      Citations: 1     Fields:    Translation:Humans
    36. Pyzer AR, Dillon LW, Sharon E, Karrison TG, Zha Y, Fulton N, Gui G, Andrew G, Streicher H, Sweet K, Yaghmour G, Liu JJ, Jonas BA, Schimmer AD, Grant S, Zeidan AM, Hildebrandt GC, Lowrey CH, Mattison RJ, Palmisiano N, Salhotra A, Tzachanis D, Baer MR, Lin TL, Patel P, Chen H, Stadler WM, Odenike O, Larson RA, Gajewski TF, Hourigan CS, Stock W, Liu H. Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia. Blood Adv. 2025 May 13; 9(9):2144-2152. PMID: 39928953; PMCID: PMC12051614.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    37. DaSilva B, Darwin A, Zhang A, Vyas RD, Russell K, Gilbert JS, Tan V, Feldt S, Johnston H, Liang EC, DuVall AS, Liedtke M, Stock W, Cassaday RD, Schwartz M, Leonard JT, Muffly LS, Luskin MR. Real-world performance of the CALGB 10403 regimen in young adults in the United States. Blood Neoplasia. 2025 Aug; 2(3):100111. PMID: 40792014; PMCID: PMC12335966.
      Citations:    
    38. Advani A, Wolfson JA, Grimes AC, Nuño MM, Ramakrishnan S, Dickens DS, Roth ME, Woods W, Adams KS, Alabi T, Beauchemin M, Levine JM, Scialla M, Boayue KB, Kerber CL, Ponce O, Vargas S, Chang GJ, Stock W, Hershman D, Curran E, O'Dwyer K, Luger S, Liu JJ, Freyer DR, Sung L, Parsons SK. Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemia. JNCI Cancer Spectr. 2025 Apr 30; 9(3). PMID: 40238217; PMCID: PMC12121638.
      Citations:    Fields:    Translation:Humans
    39. Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Patel PA, Collins RH, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Redner RL, Kovacsovics T, Deininger MW, Zeidner JF, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran EK, Koenig KL, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF. Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial. Blood Cancer J. 2025 Apr 03; 15(1):55. PMID: 40180903; PMCID: PMC11968959.
      Citations: 3     Fields:    
    40. Short NJ, Aldoss I, DeAngelo DJ, Konopleva M, Leonard J, Logan AC, Park J, Shah B, Stock W, Jabbour E. Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts. Blood Adv. 2025 Mar 25; 9(6):1442-1451. PMID: 39853316; PMCID: PMC11960638.
      Citations: 12     Fields:    Translation:Humans
    41. Escherich CS, Moriyama T, Li Z, Hsiao YC, Yang W, Li Y, Reyes N, Walker M, Budhraja A, Bhatara S, Diaz-Flores E, Stock W, Paietta E, Konopleva MY, Kornblau SM, Litzow MR, Inaba H, Pui CH, Opferman JT, Loh ML, Yu J, O'Brien MM, Evans WE, Yang JJ. DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia. Blood. 2025 Mar 13; 145(11):1182-1194. PMID: 39791601; PMCID: PMC11923432.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    42. Luskin MR, Yin J, Lozanski G, Curran E, Malnassy G, Mrózek K, Bloomfield CD, Cataland SR, Fulton N, Kolitz J, Laplant B, Kour O, Powell BL, Vij R, Wang ES, Grinblatt D, Stone RM, Uy GL, Larson RA, Stock W. Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study. Cancer. 2025 Feb 15; 131(4):e35750. PMID: 39916320; PMCID: PMC11803179.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    43. Luskin MR, Murakami MA, Keating J, Flamand Y, Winer ES, Garcia JS, Stahl M, Stone RM, Wadleigh M, Jaeckle SL, Hagopian E, Weinstock DM, Liegel J, McMasters M, Wang ES, Stock W, DeAngelo DJ. Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia. Blood. 2025 02 06; 145(6):577-589. PMID: 39374521; PMCID: PMC12782964.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    44. Zhang XE, Cornwell P, Bai S, Mertens AC, Lipscomb J, Castellino SM, Ji X, Yabroff KR, Stock W. Health insurance continuity and mortality in children, adolescents, and young adults with blood cancer. J Natl Cancer Inst. 2025 Feb 01; 117(2):344-354. PMID: 39276159; PMCID: PMC11807435.
      Citations: 1     Fields:    Translation:Humans
    45. Zhang XE, Castellino SM, Yabroff KR, Stock W, Cornwell P, Bai S, Mertens AC, Lipscomb J, Ji X. Medicaid coverage continuity is associated with lymphoma stage among children and adolescents/young adults. Blood Adv. 2025 Jan 28; 9(2):280-290. PMID: 39531060; PMCID: PMC11786654.
      Citations:    Fields:    Translation:Humans
    46. Anabtawi N, Nicolet D, Alotaibi N, Buelow DR, Orwick S, Gregory T, Raj R, Coleman K, Kolitz JE, Powell BL, Blum WG, Baer MR, Byrd JC, Stock W, Uy GL, Mrózek K, Eisfeld AK, Cheng X, Baker SD, Blachly JS. Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies. Leukemia. 2025 Mar; 39(3):623-631. PMID: 39806020; PMCID: PMC11879849.
      Citations: 3     Fields:    Translation:HumansCells
    47. Madero-Marroquin R, Hunter RW, Saygin C, Johnston H, DuVall AS, Rahmani Youshanlouei H, Osei C, Shah S, Stock W, Gurbuxani S, Patel AA. CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia. EJHaem. 2025 Feb; 6(1):e1076. PMID: 39866945; PMCID: PMC11756963.
      Citations: 1     
    48. Aldoss I, Roloff GW, Faramand R, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Zhang A, Miller K, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Dholaria B, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Logan AC, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine J, Solh MM, Lee CJ, Kota VK, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat V, Shah BD, Muffly LS. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024 Dec 10; 8(23):6139-6147. PMID: 39093952; PMCID: PMC11707416.
      Citations: 7     Fields:    Translation:Humans
    49. Lin C, Patel AA, Huo D, Karrison T, van Besien K, Godwin J, Sher D, Weiner H, Green M, Wade JL, Klisovic R, Baer MR, Larson RA, Stock W, Odenike O. A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 11 26; 8(22):5735-5743. PMID: 39250708; PMCID: PMC11599980.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    50. Aldoss I, Zhang J, Shimamoto K, Saygin C, Robbins M, Agrawal V, Aribi A, Karaoglu DA, Pourhassan H, Koller P, Ali H, Blackmon A, Otoukesh S, Sandhu K, Ball B, Artz AS, Al Malki MM, Salhotra A, Tinajero J, Gu Z, Lagman I, Velasquez M, Dang J, Becker PS, Afkhami M, Ghoda L, Stock W, Forman SJ, Stein A, Marcucci G, Pullarkat V. Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica. 2025 05 01; 110(5):1105-1114. PMID: 39506897; PMCID: PMC12050928.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    51. Roloff GW, Kosuri S, Nawas MT, DuVall AS, Patel AA, Riedell PA, Odenike O, Stock W, Larson RA, Bishop MR, Nunley E, Godley LA, Hathaway F, Del Gaudio D, Das S, Canham LE, Drazer MW. Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Nov 01; 109(11):3739-3744. PMID: 38618681; PMCID: PMC11532700.
      Citations: 2     Fields:    
    52. Hoff FW, Blum WG, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Archer KJ, Patel PA, Collins RH, Baer MR, Duong VH, Arellano ML, Stock W, Odenike O, Redner RL, Kovacsovics T, Deininger MW, Zeidner JF, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran EK, Koenig KL, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF. Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Blood Adv. 2024 10 22; 8(20):5297-5305. PMID: 39110987; PMCID: PMC11497398.
      Citations: 11     Fields:    Translation:Humans
    53. Archer KJ, Fu H, Mrózek K, Nicolet D, Mims AS, Uy GL, Stock W, Byrd JC, Hiddemann W, Metzeler KH, Rausch C, Krug U, Sauerland C, Görlich D, Berdel WE, Woermann BJ, Braess J, Spiekermann K, Herold T, Eisfeld AK. Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia. Innovation (Camb). 2024 Nov 04; 5(6):100719. PMID: 39529956; PMCID: PMC11551470.
      Citations: 2     
    54. Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L, ROCCA Consortium. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. J Clin Oncol. 2025 02 10; 43(5):558-566. PMID: 39418622; PMCID: PMC12070553.
      Citations: 16     Fields:    Translation:Humans
    55. Stiff A, Fornerod M, Kain BN, Nicolet D, Kelly BJ, Miller KE, Mrózek K, Boateng I, Bollas A, Garfinkle EAR, Momoh O, Fasola FA, Olawumi HO, Mencia-Trinchant N, Kloppers JF, van Marle AC, Hu E, Wijeratne S, Wheeler G, Walker CJ, Buss J, Heyrosa A, Desai H, Laganson A, Hamp E, Abu-Shihab Y, Abaza H, Kronen P, Sen S, Johnstone ME, Quinn K, Wronowski B, Hertlein E, Miles LA, Mims AS, Oakes CC, Blachly JS, Larkin KT, Mundy-Bosse B, Carroll AJ, Powell BL, Kolitz JE, Stone RM, Duarte C, Abbott D, Amaya ML, Jordan CT, Uy GL, Stock W, Archer KJ, Paskett ED, Guzman ML, Levine RL, Menghrajani K, Chakravarty D, Berger MF, Bottomly D, McWeeney SK, Tyner JW, Byrd JC, Salomonis N, Grimes HL, Mardis ER, Eisfeld AK. Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia. Nat Genet. 2024 Nov; 56(11):2434-2446. PMID: 39367245; PMCID: PMC11549055.
      Citations: 10     Fields:    Translation:HumansCells
    56. Bleyer A, Tai E, Siegel S, Roth M, DeAngelo DJ, Stock W. Abatement of the Survival Cliff in Older Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma in the United States. J Adolesc Young Adult Oncol. 2025 02; 14(1):33-42. PMID: 39321033; PMCID: PMC12051159.
      Citations:    Fields:    Translation:Humans
    57. Palmer A, Rauscher G, Abraham I, Burkart M, Dave A, Raptis N, Aleem A, Gannamani V, Erra A, Monick S, Galvez C, Shah S, Rahmani Youshanlouei H, Larson ML, Zia M, Tsai SB, Altman JK, Stock W, Khan I, Patel AA. Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia. Blood Adv. 2024 09 10; 8(17):4647-4650. PMID: 38810264; PMCID: PMC11402143.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    58. Yoshimura S, Li Z, Gocho Y, Yang W, Crews KR, Lee SHR, Roberts KG, Mullighan CG, Relling MV, Yu J, Yeoh AEJ, Loh ML, Saygin C, Litzow MR, Jeha S, Karol SE, Inaba H, Pui CH, Konopleva M, Jain N, Stock W, Paietta E, Jabbour E, Kornblau SM, Evans WE, Yang JJ. Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2024 10 10; 42(29):3478-3490. PMID: 39102629; PMCID: PMC11458355.
      Citations: 8     Fields:    Translation:Humans
    59. Zhao Y, Laird AD, Roberts KG, Yafawi R, Kantarjian H, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien S, Jabbour E, Cassaday RD, Loyd MR, Olsen S, Neale G, Liu X, Vandendries E, Advani A, Mullighan CG. Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL. Blood Adv. 2024 06 25; 8(12):3226-3236. PMID: 38607410; PMCID: PMC11225676.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    60. Archer KJ, Fu H, Mrózek K, Nicolet D, Mims AS, Uy GL, Stock W, Byrd JC, Hiddemann W, Braess J, Spiekermann K, Metzeler KH, Herold T, Eisfeld AK. Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model. J Hematol Oncol. 2024 05 03; 17(1):28. PMID: 38702786; PMCID: PMC11068580.
      Citations: 2     Fields:    Translation:Humans
    61. Bhattarai KR, Mobley RJ, Barnett KR, Ferguson DC, Hansen BS, Diedrich JD, Bergeron BP, Yoshimura S, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Cheng C, Pruett-Miller SM, Relling MV, Yang JJ, Evans WE, Savic D. Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment. Nat Commun. 2024 May 01; 15(1):3681. PMID: 38693155; PMCID: PMC11063049.
      Citations: 6     Fields:    Translation:HumansCells
    62. Saygin C, Zhang P, Stauber J, Aldoss I, Sperling AS, Weeks LD, Luskin MR, Knepper TC, Wanjari P, Wang P, Lager AM, Fitzpatrick C, Segal JP, Gharghabi M, Gurbuxani S, Venkataraman G, Cheng JX, Eisfelder BJ, Bohorquez O, Patel AA, Umesh Nagalakshmi S, Jayaram S, Odenike OM, Larson RA, Godley LA, Arber DA, Gibson CJ, Munshi NC, Marcucci G, Ebert BL, Greally JM, Steidl U, Lapalombella R, Shah BD, Stock W. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 05 01; 5(3):164-179. PMID: 38150184; PMCID: PMC11061587.
      Citations: 13     Fields:    Translation:Humans
    63. Patkowska E, Roboz GJ, Sanz G, Griffiths EA, Yee K, Kantarjian H, Récher C, Byrne MT, Kim HJ, Thomas X, Moors I, Stock W, Illés Á, Fenaux P, Miyazaki Y, Yamauchi T, O'Connell CL, Hao Y, Keer HN, Azab M, Döhner H. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial. Blood Adv. 2024 04 23; 8(8):2020-2029. PMID: 38231126; PMCID: PMC11103175.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    64. Woyach JA, Perez Burbano G, Ruppert AS, Miller C, Heerema NA, Zhao W, Wall A, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Stephens DM, Brown JR, Lozanski G, Blachly J, Nattam S, Larson RA, Erba H, Litzow M, Luger S, Owen C, Kuzma C, Abramson JS, Little RF, Dinner S, Stone RM, Uy G, Stock W, Mandrekar SJ, Byrd JC. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024 04 18; 143(16):1616-1627. PMID: 38215395; PMCID: PMC11103091.
      Citations: 25     Fields:    Translation:Humans
    65. Huang X, Li Y, Zhang J, Yan L, Zhao H, Ding L, Bhatara S, Yang X, Yoshimura S, Yang W, Karol SE, Inaba H, Mullighan C, Litzow M, Zhu X, Zhang Y, Stock W, Jain N, Jabbour E, Kornblau SM, Konopleva M, Pui CH, Paietta E, Evans W, Yu J, Yang JJ. Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia. Cancer Cell. 2024 04 08; 42(4):552-567.e6. PMID: 38593781; PMCID: PMC11008188.
      Citations: 20     Fields:    Translation:HumansCells
    66. He G, Belmont E, Karrison T, Stock W, LaBelle JL, Kosuri S, Larson RA, Kline JP, Riedell PA, Nawas M, Bishop MR, Liu H. FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients. Ann Transl Med. 2024 Jun 10; 12(3):49. PMID: 38911560; PMCID: PMC11193555.
      Citations:    
    67. Madero-Marroquin R, Dworkin E, Weiner H, Saygin C, Nawas MT, Drazer MW, DuVall AS, Kosuri S, Thirman MJ, Odenike O, Stock W, Larson RA, Patel AA. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 06; 65(6):864-867. PMID: 38441062.
      Citations: 1     Fields:    Translation:Humans
    68. Cai SF, Huang Y, Lance JR, Mao HC, Dunbar AJ, McNulty SN, Druley T, Li Y, Baer MR, Stock W, Kovacsovics T, Blum WG, Schiller GJ, Olin RL, Foran JM, Litzow M, Lin T, Patel P, Foster MC, Boyiadzis M, Collins RH, Chervin J, Shoben A, Vergilio JA, Heerema NA, Rosenberg L, Chen TL, Yocum AO, Druggan F, Marcus S, Stefanos M, Druker BJ, Mims AS, Borate U, Burd A, Byrd JC, Levine RL, Stein EM. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood Adv. 2024 01 23; 8(2):429-440. PMID: 37871309; PMCID: PMC10827405.
      Citations: 11     Fields:    Translation:Humans
    69. Wolfson JA, Grimes AC, Nuno M, Kerber CL, Ramakrishnan S, Beauchemin M, Dickens D, Levine JM, Roth ME, Scialla M, Woods W, Vargas S, Boayue KB, Chang GJ, Stock W, Hershman D, Curran E, Advani A, O'Dwyer K, Luger S, Liu JJ, Freyer DR, Sung L, Parsons SK. Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL. JCO Oncol Pract. 2024 04; 20(4):491-502. PMID: 38252911; PMCID: PMC11085951.
      Citations: 2     Fields:    Translation:Humans
    70. Johnston H, Youshanlouei HR, Osei C, Patel AA, DuVall A, Wang P, Wanjari P, Segal J, Venkataraman G, Cheng JX, Gurbuxani S, Lager A, Fitzpatrick C, Thirman M, Nawas M, Liu H, Drazer M, Odenike O, Larson R, Stock W, Saygin C. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171. PMID: 38039510; PMCID: PMC10787242.
      Citations: 6     Fields:    Translation:Humans
    71. Parriott G, Hegermiller E, Morman RE, Frank C, Saygin C, Stock W, Bartom ET, Kee BL. Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALL. Leukemia. 2024 03; 38(3):491-501. PMID: 38155245; PMCID: PMC12523820.
      Citations: 1     Fields:    Translation:AnimalsCells
    72. Madero-Marroquin R, DuVall AS, Saygin C, Wang P, Gurbuxani S, Larson RA, Stock W, Patel AA. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 04; 204(4):1238-1242. PMID: 38073116.
      Citations: 5     Fields:    Translation:Humans
    73. Iacobucci I, Zeng AGX, Gao Q, Garcia-Prat L, Baviskar P, Shah S, Murison A, Voisin V, Chan-Seng-Yue M, Cheng C, Qu C, Bailey C, Lear M, Witkowski MT, Zhou X, Peraza AZ, Gangwani K, Advani AS, Luger SM, Litzow MR, Rowe JM, Paietta EM, Stock W, Dick JE, Mullighan CG. SINGLE CELL DISSECTION OF DEVELOPMENTAL ORIGINS AND TRANSCRIPTIONAL HETEROGENEITY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. bioRxiv. 2023 Dec 09. PMID: 38106088; PMCID: PMC10723356.
      Citations: 1     
    74. Ozga M, Nicolet D, Mrózek K, Yilmaz AS, Kohlschmidt J, Larkin KT, Blachly JS, Oakes CC, Buss J, Walker CJ, Orwick S, Jurinovic V, Rothenberg-Thurley M, Dufour A, Schneider S, Sauerland MC, Görlich D, Krug U, Berdel WE, Woermann BJ, Hiddemann W, Braess J, Subklewe M, Spiekermann K, Carroll AJ, Blum WG, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Uy GL, Stock W, Metzeler KH, Grimes HL, Byrd JC, Salomonis N, Herold T, Mims AS, Eisfeld AK. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). Leukemia. 2024 01; 38(1):45-57. PMID: 38017103; PMCID: PMC10776397.
      Citations: 24     Fields:    Translation:Humans
    75. Fan H, Xia S, Xiang J, Li Y, Ross MO, Lim SA, Yang F, Tu J, Xie L, Dougherty U, Zhang FQ, Zheng Z, Zhang R, Wu R, Dong L, Su R, Chen X, Althaus T, Riedell PA, Jonker PB, Muir A, Lesinski GB, Rafiq S, Dhodapkar MV, Stock W, Odenike O, Patel AA, Opferman J, Tsuji T, Matsuzaki J, Shah H, Faubert B, Elf SE, Layden B, Bissonnette BM, He YY, Kline J, Mao H, Odunsi K, Gao X, Chi H, He C, Chen J. Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity. Nature. 2023 11; 623(7989):1034-1043. PMID: 37993715; PMCID: PMC10686835.
      Citations: 54     Fields:    Translation:HumansAnimalsCells
    76. Monovich AC, Narina S, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Ryan RJH, Barnett KR, Mobley RJ, Diedrich JD, Bergeron BP, Bhattarai KR, Yang W, Crews KR, Inaba H, Jeha S, Pui CH, Mullighan CG, Relling MV, Pruett-Miller SM, Yang JJ, Evans WE, Savic D. Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators. Cell Genom. 2023 12 13; 3(12):100442. PMID: 38116118; PMCID: PMC10726428.
      Citations: 11     Fields:    
    77. Ravandi F, Bashey A, Foran J, Stock W, Mawad R, Short N, Yilmaz M, Kantarjian H, Odenike O, Patel A, Garcha R, Ainsworth WB, Clynes R, Kanodia J, Ding Y, Li H, Kye S, Mims A. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv. 2023 11 14; 7(21):6492-6505. PMID: 37647601; PMCID: PMC10632668.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    78. Rosenberg SM, McCue S, He J, Lafky JM, Carey LA, Galanis E, Leonard JP, Meyerhardt J, Ng K, Schwartz GK, Stock W, Paskett ED, Partridge AH, George S. Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017. Cancer. 2024 03 01; 130(5):750-769. PMID: 37916800; PMCID: PMC10922614.
      Citations: 2     Fields:    Translation:Humans
    79. Borate U, Yang F, Press R, Ruppert AS, Jones D, Caruthers S, Zhao W, Vergilio JA, Pavlick DC, Juckett L, Norris B, Bucy T, Burd A, Stein EM, Patel P, Baer MR, Stock W, Schiller G, Blum W, Kovacsovics T, Litzow M, Foran J, Heerema NA, Rosenberg L, Marcus S, Yocum A, Stefanos M, Druker B, Byrd JC, Levine RL, Mims A. Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories. Blood Adv. 2023 10 24; 7(20):6048-6054. PMID: 37459200; PMCID: PMC10582272.
      Citations: 3     Fields:    Translation:Humans
    80. Neme-Yunes Y, Rangel-Patiño J, Lee-Tsai YL, Urbalejo-Ceniceros VI, Luna-Perez MEM, Espinosa-Bautista KA, Amador LF, Cabrera-García Á, Balderas-Delgado C, Inclan-Alarcon SI, Sanchez-Albarrán JM, Apodaca EI, Meillon-García L, Stock W, Demichelis-Gómez R. A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America. Blood Adv. 2023 09 26; 7(18):5202-5209. PMID: 37307212; PMCID: PMC10500455.
      Citations: 4     Fields:    Translation:Humans
    81. Bhatnagar B, Kohlschmidt J, Orwick SJ, Buelow DR, Fobare S, Oakes CC, Kolitz JE, Uy G, Stock W, Powell BL, Nicolet D, Hertlein EK, Mrózek K, Blachly JS, Eisfeld AK, Baker SD, Byrd JC. Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study. Blood Adv. 2023 08 22; 7(16):4671-4675. PMID: 37603350; PMCID: PMC10448419.
      Citations: 1     Fields:    Translation:Humans
    82. Bhatnagar B, Kohlschmidt J, Orwick S, Buelow DR, Fobare S, Oakes CC, Kolitz JE, Uy GL, Stock W, Powell BL, Nicolet D, Hertlein E, Mrózek K, Blachly JS, Eisfeld AK, Baker SD, Byrd JC, Bhatnagar B, Kohlschmidt J, Orwick SJ, Buelow DR, Fobare S, Oakes CC, Kolitz JE, Uy G, Stock W, Powell BL, Nicolet D, Hertlein EK, Mrózek K, Blachly JS, Eisfeld AK, Baker SD, Byrd JC. Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study. Blood Adv. 2023 Aug 22; 7(16):4671-4675. PMID: 37289505.
      Citations:    Fields:    
    83. Saygin C, Giordano G, Shimamoto K, Eisfelder B, Thomas-Toth A, Venkataraman G, Ananthanarayanan V, Vincent TL, DuVall A, Patel AA, Chen Y, Tan F, Anthony SP, Chen Y, Shen Y, Odenike O, Teachey DT, Kee BL, LaBelle J, Stock W. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clin Cancer Res. 2023 08 15; 29(16):3151-3161. PMID: 37363966; PMCID: PMC10425730.
      Citations: 12     Fields:    Translation:HumansCells
    84. Vesely SK, King A, Vettese E, Heller JG, Cuker A, Calhoun C, Stock W, Homer M, Fritz J, Sung L. Influence of participant and reviewer characteristics in application scores for a hematology research training program. Blood Adv. 2023 08 08; 7(15):4064-4071. PMID: 36939221; PMCID: PMC10388723.
      Citations:    Fields:    Translation:Humans
    85. Rowland L, Smart B, Brown A, Dettorre GM, Gocho Y, Hunt J, Yang W, Yoshimura S, Reyes N, Du G, John A, Maxwell D, Stock W, Kornblau S, Relling MV, Inaba H, Pui CH, Bourquin JP, Karol SE, Mullighan CG, Evans WE, Yang JJ, Crews KR. Ex vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia Cells. Bio Protoc. 2023 Aug 05; 13(15):e4731. PMID: 37575398; PMCID: PMC10415213.
      Citations: 6     
    86. Roloff GW, Wen F, Ramsland A, Artz AS, Kosuri S, Stock W, Odenike O, Larson RA, Liu H, Godley LA, Thirman MJ, Patel AA, Daugherty CK, DuVall AS, Nawas MT, Dworkin E, Wool GD, Gurbuxani S, Fitzpatrick C, Segal JP, Wang P, Drazer MW. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239. PMID: 36655425; PMCID: PMC10388285.
      Citations: 1     Fields:    Translation:Humans
    87. Barnett KR, Mobley RJ, Diedrich JD, Bergeron BP, Bhattarai KR, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Mullighan CG, Relling MV, Yang JJ, Evans WE, Savic D. Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architectures. bioRxiv. 2023 Jul 13. PMID: 36824825; PMCID: PMC9949063.
      Citations:    
    88. Gallardo-Pérez MM, Gale RP, Reyes-Cisneros OA, Sánchez-Bonilla D, Fernández-Gutiérrez JA, Stock W, Murrieta-Álvarez I, Olivares-Gazca JC, Ruiz-Delgado GJ, Fonseca R, Ruiz-Argüelles GJ. Therapy of childhood acute lymphoblastic leukemia in resource-poor geospaces. Front Oncol. 2023; 13:1187268. PMID: 37397374; PMCID: PMC10312136.
      Citations: 1     
    89. Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger M, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis MM, Traer E, Odenike O, Arellano ML, Walker A, Duong VH, Kovacsovics T, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana TJ, Rosenberg L, Marcus S, Yocum AO, Chen T, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM. Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood Adv. 2023 06 13; 7(11):2360-2363. PMID: 36315007; PMCID: PMC10230164.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    90. Liang G, Wang L, You Q, Cahill K, Chen C, Zhang W, Fulton N, Stock W, Odenike O, He C, Han D. Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy. Adv Sci (Weinh). 2023 08; 10(23):e2300445. PMID: 37271891; PMCID: PMC10427370.
      Citations: 8     Fields:    Translation:Humans
    91. Parriott G, Hegermiller E, Morman RE, Frank C, Saygin C, Stock W, Bartom ET, Kee BL. Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T lymphocyte acute lymphoblastic leukemia. bioRxiv. 2023 Apr 25. PMID: 37163059; PMCID: PMC10168235.
      Citations:    
    92. Duong VH, Ruppert AS, Mims AS, Borate U, Stein EM, Baer MR, Stock W, Kovacsovics T, Blum W, Arellano ML, Schiller GJ, Olin RL, Foran JM, Litzow MR, Lin TL, Patel PA, Foster MC, Redner RL, Al-Mansour Z, Cogle CR, Swords RT, Collins RH, Vergilio JA, Heerema NA, Rosenberg L, Yocum AO, Marcus S, Chen T, Druggan F, Stefanos M, Gana TJ, Shoben AB, Druker BJ, Burd A, Byrd JC, Levine RL, Boyiadzis MM. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. Cancer. 2023 08 01; 129(15):2308-2320. PMID: 37078412; PMCID: PMC11225573.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    93. Yoshimura S, Panetta JC, Hu J, Li L, Gocho Y, Du G, Umezawa A, Karol SE, Pui CH, Mullighan CG, Konopleva M, Stock W, Teachey DT, Jain N, Yang JJ. Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia. Leukemia. 2023 06; 37(6):1194-1203. PMID: 37076694; PMCID: PMC10347458.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    94. Bhatt VR, Ulrich AM, Uy GL, Stone RM, Stock W, Ojelabi MO, Yin J, Kohlschmidt J, Eisfeld AK, Baer MR, Chow S, Klepin H, Le-Rademacher J, Jatoi A. Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials. JCO Oncol Pract. 2023 06; 19(6):e877-e891. PMID: 37058684; PMCID: PMC10332839.
      Citations: 3     Fields:    Translation:Humans
    95. Godfrey J, Liu H, Yu J, Tallarico M, Curran E, Artz A, Riedell PA, Stock W, Karrison T, Fitzpatrick C, Venkataraman G, Cooper A, Smith SM, Bishop MR, Kline J. Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2023 03 28; 7(6):963-970. PMID: 35973200; PMCID: PMC10027501.
      Citations: 15     Fields:    Translation:HumansAnimals
    96. Kohlschmidt J, Blachly JS, Nicolet D, Carroll AJ, Archer KJ, Mims AS, Larkin KT, Orwick S, Oakes CC, Kolitz JE, Powell BL, Blum WG, Marcucci G, Baer MR, Uy GL, Stock W, Byrd JC, Eisfeld AK, Mrózek K. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia. 2023 04; 37(4):788-798. PMID: 36823396; PMCID: PMC10079544.
      Citations: 44     Fields:    Translation:Humans
    97. Tran MC, Hasan Y, Wang A, Yenice K, Partouche J, Stock W, Larson RA, Kosuri S, LaBelle JL, Kline J, Riedell PA, Artz AS, Weichselbaum R, Bishop MR, Aydogan B, Liu H. A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292. PMID: 35851593; PMCID: PMC9898602.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    98. Bhattarai KR, Mobley RJ, Barnett KR, Ferguson DC, Hansen BS, Diedrich JD, Bergeron BP, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Cheng C, Pruett-Miller SM, Relling MV, Yang JJ, Evans WE, Savic D. Functional investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment. medRxiv. 2023 Feb 11. PMID: 36798219; PMCID: PMC9934807.
      Citations:    
    99. Aldoss I, Shah BD, Park JH, Muffly L, Logan AC, Brown P, Stock W, Jabbour EJ. Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Am J Hematol. 2023 04; 98(4):666-680. PMID: 36691748.
      Citations: 7     Fields:    Translation:Humans
    100. Aldoss I, Yin J, Wall A, Liedtke M, Claxton DF, Foster MC, Appelbaum FR, Erba HP, Litzow MR, Tallman MS, Stone RM, Larson RA, Advani AS, Stock W, Luger SM, Mrózek K. The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study. Blood Adv. 2023 01 24; 7(2):196-204. PMID: 36269846; PMCID: PMC9841239.
      Citations: 7     Fields:    Translation:Humans
    101. Alqahtani A, Alhousari D, Ali A, Yaghmour G, Orgel E, Curran E, Stock W, Bhojwani D, Alachkar H. Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding. Expert Opin Drug Metab Toxicol. 2023 Jan-Jun; 19(6):357-366. PMID: 37410014; PMCID: PMC11516125.
      Citations: 1     Fields:    Translation:Humans
    102. Saygin C, Cannova J, Stock W, Muffly L. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica. 2022 12 01; 107(12):2783-2793. PMID: 36453516; PMCID: PMC9713546.
      Citations: 40     Fields:    Translation:Humans
    103. Alban J, DuVall A, Gurbuxani S, Stock W, Patel AA. Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2022 10; 6:e2200353. PMID: 36240471; PMCID: PMC9616637.
      Citations: 2     Fields:    Translation:HumansCells
    104. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Godley LA, Gotlib J, Hobbs GS, Hoffman R, Jabbour EJ, Larson RA, Le Beau MM, Loh ML, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Tefferi A, Kvasnicka HM, Dombret H, Gianelli U, Gökbuget N, Hellström-Lindberg E, Kiladjian JJ, Löwenberg B, Macintyre E, Thiele J, Döhner H. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228. PMID: 35767897; PMCID: PMC9479031.
      Citations: 1320     Fields:    Translation:Humans
    105. Anderson DR, Stock W, Karrison TG, Leader A. D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia. Blood Adv. 2022 09 13; 6(17):5146-5151. PMID: 35728059; PMCID: PMC9631615.
      Citations: 11     Fields:    Translation:Humans
    106. Muffly L, Yin J, Jacobson S, Wall A, Quiroz E, Advani AS, Luger SM, Tallman MS, Litzow MR, Foster MC, Erba HP, Appelbaum FR, Larson RA, Keegan THM, Stock W. Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. Blood Adv. 2022 07 26; 6(14):4085-4092. PMID: 35838753; PMCID: PMC9327550.
      Citations: 12     Fields:    Translation:Humans
    107. Maristany S, DuVall AS, Stock W, Adeleye AJ. Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents. J Assist Reprod Genet. 2022 Aug; 39(8):1733-1738. PMID: 35727422; PMCID: PMC9209836.
      Citations: 3     Fields:    Translation:Humans
    108. Kimura S, Montefiori L, Iacobucci I, Zhao Y, Gao Q, Paietta EM, Haferlach C, Laird AD, Mead PE, Gu Z, Stock W, Litzow M, Rowe JM, Luger SM, Hunger SP, Ryland GL, Schmidt B, Ekert PG, Oshlack A, Grimmond SM, Rehn J, Breen J, Yeung D, White DL, Aldoss I, Jabbour EJ, Pui CH, Meggendorfer M, Walter W, Kern W, Haferlach T, Brady S, Zhang J, Roberts KG, Blombery P, Mullighan CG. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood. 2022 06 16; 139(24):3519-3531. PMID: 35192684; PMCID: PMC9203703.
      Citations: 24     Fields:    Translation:HumansCells
    109. Epstein-Peterson ZD, Derkach A, Geyer S, Kohlschmidt J, Park JH, Rajeeve S, Stein EM, Zhang Y, Iland H, Campbell LJ, Larson RA, Powell BL, Stock W, Stone RM, Tallman MS, Mrózek K, Poiré X. Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. Blood Adv. 2022 06 14; 6(11):3433-3439. PMID: 35349669; PMCID: PMC9198910.
      Citations: 9     Fields:    Translation:Humans
    110. Ferguson DC, McCorkle JR, Barnett KR, Bonten EJ, Bergeron BP, Bhattarai KR, Yang W, Smith C, Hansen BS, Bajpai R, Dong Q, Autry RJ, Gocho Y, Diedrich JD, Crews KR, Pruett-Miller SM, Roberts KG, Stock W, Mullighan CG, Inaba H, Jeha S, Pui CH, Yang JJ, Relling MV, Evans WE, Savic D. Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia. Blood Adv. 2022 06 14; 6(11):3386-3397. PMID: 35671062; PMCID: PMC9198938.
      Citations: 10     Fields:    Translation:HumansCells
    111. Hantel A, Kohlschmidt J, Eisfeld AK, Stock W, Jacobson S, Mandrekar S, Larson RA, Stone RM, Lathan CS, DeAngelo DJ, Byrd JC, Abel GA. Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. J Clin Oncol. 2022 11 10; 40(32):3709-3718. PMID: 35696629; PMCID: PMC9649272.
      Citations: 13     Fields:    Translation:Humans
    112. Hetzel S, Mattei AL, Kretzmer H, Qu C, Chen X, Fan Y, Wu G, Roberts KG, Luger S, Litzow M, Rowe J, Paietta E, Stock W, Mardis ER, Wilson RK, Downing JR, Mullighan CG, Meissner A. Acute lymphoblastic leukemia displays a distinct highly methylated genome. Nat Cancer. 2022 06; 3(6):768-782. PMID: 35590059; PMCID: PMC9236905.
      Citations: 30     Fields:    Translation:HumansCells
    113. Wu S, Wang M, Alqahtani A, Lou M, Stock W, Bhojwani D, Alachkar H. Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia. Biomed Pharmacother. 2022 Jun; 150:113000. PMID: 35658244; PMCID: PMC9450009.
      Citations: 7     Fields:    Translation:Humans
    114. Abraham IE, Rauscher GH, Patel AA, Pearse WB, Rajakumar P, Burkart M, Aleem A, Dave A, Bharadwaj S, Paydary K, Acevedo-Mendez M, Goparaju K, Gomez R, Carlson K, Tsai SB, Quigley JG, Galvin JP, Zia M, Larson ML, Berg S, Stock W, Altman JK, Khan I. Structural racism is a mediator of disparities in acute myeloid leukemia outcomes. Blood. 2022 04 07; 139(14):2212-2226. PMID: 35061876; PMCID: PMC9710198.
      Citations: 50     Fields:    Translation:Humans
    115. DuVall AS, Sheade J, Anderson D, Yates SJ, Stock W. Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered! JCO Oncol Pract. 2022 07; 18(7):479-487. PMID: 35380890.
      Citations: 19     Fields:    Translation:Humans
    116. Kaumeyer B, Fidai S, Sukhanova M, Yap KL, Segal J, Raca G, Stock W, McNeer J, Lager AM, Gurbuxani S. MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia. Leuk Lymphoma. 2022 06; 63(6):1436-1444. PMID: 35171727.
      Citations: 3     Fields:    Translation:Humans
    117. Advani AS, Moseley A, O'Dwyer KM, Wood BL, Fang M, Wieduwilt MJ, Aldoss I, Park JH, Klisovic RB, Baer MR, Stock W, Bhave RR, Othus M, Harvey RC, Willman CL, Litzow MR, Stone RM, Sharon E, Erba HP. SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2022 05 10; 40(14):1574-1582. PMID: 35157496; PMCID: PMC9084435.
      Citations: 52     Fields:    Translation:HumansCellsCTClinical Trials
    118. Lin WY, Fordham SE, Hungate E, Sunter NJ, Elstob C, Xu Y, Park C, Skol A, Rahman T, Sucheston-Campbell L, Wang J, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Alharbi A, Allsup DJ, Houlston RS, Norden J, Dickinson AM, Douglas E, Lendrem C, Daly AK, Palm L, Piechocki K, Jeffries S, Altmann H, Ruhnke L, Kunadt D, Cordell HJ, Darlay R, Andersen MK, Martinelli G, Marconi G, Cluzeau T, Raynaud S, Sill H, Cheok M, Preudhomme C, Gale RE, Linch D, Gaal-Wesinger J, Masszi A, Nowak D, Hofmann WK, Gilkes A, Porkka K, Milosevic Feenstra JD, Kralovics R, Grimwade D, Meggendorfer M, Haferlach T, Onel K, Allan JM, Quante A, Strauch K, Gieger C, Bornhäuser M, Röllig C, Wagenführ L, Fontana MC, Sanz MA, Cervera J, Gómez-Seguí I, Moreilhon C, Voso MT, Lo-Coco F, Dombret H, Krizsán S, Bödör C, Stölzel F. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nat Commun. 2022 Jan 04; 13(1):2. PMID: 34983928; PMCID: PMC8727612.
      Citations: 2     Fields:    
    119. Zeidan AM, DeAngelo DJ, Palmer J, Seet CS, Tallman MS, Wei X, Raymon H, Sriraman P, Kopytek S, Bewersdorf JP, Burgess MR, Hege K, Stock W. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Ann Hematol. 2022 Mar; 101(3):557-569. PMID: 34981142; PMCID: PMC9414073.
      Citations: 56     Fields:    Translation:HumansAnimalsCTClinical Trials
    120. Wieduwilt MJ, Yin J, Wetzler M, Uy GL, Powell BL, Kolitz JE, Liedtke M, Stock W, Beumer JH, Mattison RJ, Storrick E, Christner SM, Lewis LD, Devine S, Stone RM, Larson RA. Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Adv. 2021 11 23; 5(22):4691-4700. PMID: 34492682; PMCID: PMC8759134.
      Citations: 10     Fields:    Translation:HumansCells
    121. Douer D, Stock W, Gökbuget N, Boissel N. Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia. Blood Rev. 2022 05; 53:100908. PMID: 35031177.
      Citations: 13     Fields:    Translation:Humans
    122. Zanetti C, Kumar R, Ender J, Hartmann M, Hey J, Breuer K, Weissenberger ES, Minciacchi VR, Karantanou C, Gu Z, Roberts KG, Metzler M, Stock W, Mullighan CG, Bloomfield CD, Filmann N, Bankov K, Hartmann S, Hasserjian RP, Cousins AF, Halsey C, Plass C, Lipka DB, Krause DS, Godavarthy PS. The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13. Blood. 2021 11 11; 138(19):1870-1884. PMID: 34424946; PMCID: PMC8767790.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    123. Hantel A, Luskin MR, Garcia JS, Stock W, DeAngelo DJ, Abel GA. Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials. Blood Adv. 2021 11 09; 5(21):4352-4360. PMID: 34473244; PMCID: PMC8579250.
      Citations: 21     Fields:    Translation:Humans
    124. Lin WY, Fordham SE, Hungate E, Sunter NJ, Elstob C, Xu Y, Park C, Skol A, Rahman T, Sucheston-Campbell L, Wang J, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Alharbi A, Allsup DJ, Houlston RS, Norden J, Dickinson AM, Douglas E, Lendrem C, Daly AK, Palm L, Piechocki K, Jeffries S, Altmann H, Ruhnke L, Kunadt D, Cordell HJ, Darlay R, Andersen MK, Martinelli G, Marconi G, Cluzeau T, Raynaud S, Sill H, Cheok M, Preudhomme C, Gale RE, Linch D, Gaal-Wesinger J, Masszi A, Nowak D, Hofmann WK, Gilkes A, Porkka K, Milosevic Feenstra JD, Kralovics R, Grimwade D, Meggendorfer M, Haferlach T, Onel K, Allan JM, Quante A, Strauch K, Gieger C, Bornhäuser M, Röllig C, Wagenführ L, Fontana MC, Sanz MA, Cervera J, Gómez-Seguí I, Moreilhon C, Voso MT, Lo-Coco F, Dombret H, Krizsán S, Bödör C, Stölzel F. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nat Commun. 2021 10 29; 12(1):6233. PMID: 34716350; PMCID: PMC8556284.
      Citations: 19     Fields:    Translation:Humans
    125. King AA, Vesely SK, Dadzie G, Calhoun C, Cuker A, Stock W, Walker A, Fritz J, Sung L. Self-reported positive impact of mentored clinical research training is associated with academic success in hematology. Blood Adv. 2021 07 27; 5(14):2919-2924. PMID: 34309634; PMCID: PMC8341353.
      Citations: 1     Fields:    Translation:Humans
    126. Chen D, Xia S, Zhang R, Li Y, Famulare CA, Fan H, Wu R, Wang M, Zhu AC, Elf SE, Su R, Dong L, Arellano M, Blum WG, Mao H, Lonial S, Stock W, Odenike O, Le Beau M, Boggon TJ, He C, Chen J, Gao X, Levine RL, Chen J. Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. Mol Cell. 2021 09 16; 81(18):3833-3847.e11. PMID: 34289383; PMCID: PMC8455438.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    127. Schmiegelow K, Rank CU, Stock W, Dworkin E, van der Sluis I. SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2021 11; 21(11):725-733. PMID: 34511319.
      Citations: 11     Fields:    Translation:Humans
    128. Walker AR, Marcucci G, Yin J, Blum W, Stock W, Kohlschmidt J, Carroll AJ, Eisfeld AK, Wang ES, Jacobson S, Kolitz JE, Thakuri M, Sutamtewagul G, Vij R, Stuart RK, Byrd JC, Bloomfield CD, Stone RM, Larson RA, Mrózek K. Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Adv. 2021 07 13; 5(13):2775-2787. PMID: 34251414; PMCID: PMC8288671.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    129. Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D. Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021 Jul; 35(7):2140. PMID: 34088982; PMCID: PMC8329698.
      Citations: 1     Fields:    
    130. Desai PM, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi F. Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. J Clin Oncol. 2021 10 10; 39(29):3261-3272. PMID: 34156898; PMCID: PMC8500663.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    131. Patel AA, Heng J, Dworkin E, Monick S, Derman BA, DuVall AS, Gurbuxani S, Kosuri S, Liu H, Thirman M, Godley LA, Odenike O, Larson RA, Stock W. Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem. 2021 Aug; 2(3):413-420. PMID: 35844676; PMCID: PMC9175801.
      Citations: 5     
    132. Montefiori LE, Bendig S, Gu Z, Chen X, Ma X, Murison A, Zeng A, Garcia-Prat L, Dickerson K, Iacobucci I, Abdelhamed S, Hiltenbrand R, Mead PE, Mehr CM, Xu B, Cheng Z, Chang TC, Westover T, Ma J, Stengel A, Kimura S, Qu C, Valentine MB, Rashkovan M, Luger S, Litzow MR, Rowe JM, Wang V, Yin J, Kornblau SM, Hunger SP, Loh ML, Pui CH, Yang W, Crews KR, Roberts KG, Yang JJ, Relling MV, Evans WE, Stock W, Paietta EM, Ferrando AA, Zhang J, Kern W, Haferlach T, Wu G, Dick JE, Klco JM, Haferlach C, Mullighan CG, Pölönen P, den Boer ML. Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia. Cancer Discov. 2021 11; 11(11):2846-2867. PMID: 34103329; PMCID: PMC8563395.
      Citations: 106     Fields:    Translation:HumansCells
    133. Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021 07; 35(7):2076-2085. PMID: 33785862; PMCID: PMC8257494.
      Citations: 23     Fields:    Translation:Humans
    134. Eisfelder BJ, Saygin C, Wynne J, Colton MW, Fischietti M, Beauchamp EM, Cheng JX, Odenike O, Roboz G, Alachkar H, Stock W. OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. Blood Cancer J. 2021 03 03; 11(3):48. PMID: 33658483; PMCID: PMC7930094.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    135. Kennedy AL, Myers KC, Bowman J, Gibson CJ, Camarda ND, Furutani E, Muscato GM, Klein RH, Ballotti K, Liu S, Harris CE, Galvin A, Malsch M, Dale D, Gansner JM, Nakano TA, Bertuch A, Vlachos A, Lipton JM, Castillo P, Connelly J, Churpek J, Edwards JR, Hijiya N, Ho RH, Hofmann I, Huang JN, Lamble A, Lau BW, Norkin M, Stieglitz E, Stock W, Walkovich K, Boettcher S, Brendel C, Fleming MD, Davies SM, Weller EA, Bahl C, Carter SL, Shimamura A, Lindsley RC, Keel S. Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. Nat Commun. 2021 02 26; 12(1):1334. PMID: 33637765; PMCID: PMC7910481.
      Citations: 92     Fields:    Translation:HumansCells
    136. Kantarjian HM, Stock W, Cassaday RD, DeAngelo DJ, Jabbour E, O'Brien SM, Wang T, Paccagnella ML, Nguyen K, Sleight B, Vandendries E, Neuhof A, Laird AD, Advani AS, Stelljes M. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021 05 15; 27(10):2742-2754. PMID: 33602684.
      Citations: 22     Fields:    Translation:Humans
    137. Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock W. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021 06; 11(6):1440-1453. PMID: 33593877; PMCID: PMC9533326.
      Citations: 165     Fields:    Translation:HumansCTClinical Trials
    138. Major A, Collins J, Craney C, Heitman AK, Bauer E, Zerante E, Stock W, Bishop MR, Jasielec J. Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. Leuk Lymphoma. 2021 07; 62(7):1765-1769. PMID: 33559517; PMCID: PMC8282706.
      Citations: 27     Fields:    Translation:HumansCells
    139. Advani AS, Larsen E, Laumann K, Luger SM, Liedtke M, Devidas M, Chen Z, Yin J, Foster MC, Claxton D, Coffan K, Tallman MS, Appelbaum FR, Erba H, Stone RM, Hunger SP, McNeer JL, Loh ML, Raetz E, Winick N, Carroll W, Larson RA, Stock W. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021 01 26; 5(2):504-512. PMID: 33496745; PMCID: PMC7839367.
      Citations: 32     Fields:    Translation:Humans
    140. Gocho Y, Liu J, Hu J, Yang W, Dharia NV, Zhang J, Shi H, Du G, John A, Lin TN, Hunt J, Huang X, Ju B, Rowland L, Shi L, Maxwell D, Smart B, Crews KR, Yang W, Hagiwara K, Zhang Y, Roberts K, Wang H, Jabbour E, Stock W, Eisfelder B, Paietta E, Newman S, Roti G, Litzow M, Easton J, Zhang J, Peng J, Chi H, Pounds S, Relling MV, Inaba H, Zhu X, Kornblau S, Pui CH, Konopleva M, Teachey D, Mullighan CG, Stegmaier K, Evans WE, Yu J, Yang JJ. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer. 2021 03; 2(3):284-299. PMID: 34151288; PMCID: PMC8208590.
      Citations: 75     Fields:    Translation:HumansCells
    141. Prescott K, Jacobs M, Stock W, Wynne J. New Approaches to Treating Challenging Subtypes of ALL in AYA Patients. Curr Hematol Malig Rep. 2020 12; 15(6):424-435. PMID: 32920736; PMCID: PMC8279222.
      Citations: 4     Fields:    Translation:HumansCells
    142. Stock W, Martinelli G, DeAngelo DJ, Advani AS, O'Brien S, Liedtke M, Merchant AA, Cassaday RD, Wang T, Zhang H, Vandendries E, Jabbour E, Marks DI, Kantarjian HM, Stelljes M, Gökbuget N. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 03 15; 127(6):905-913. PMID: 33231879; PMCID: PMC7983935.
      Citations: 38     Fields:    Translation:HumansCells
    143. Burd A, Levine RL, Ruppert AS, Mims AS, Borate U, Stein EM, Patel P, Baer MR, Stock W, Deininger M, Blum W, Schiller G, Olin R, Litzow M, Foran J, Lin TL, Ball B, Boyiadzis M, Traer E, Odenike O, Arellano M, Walker A, Duong VH, Kovacsovics T, Collins R, Shoben AB, Heerema NA, Foster MC, Vergilio JA, Brennan T, Vietz C, Severson E, Miller M, Rosenberg L, Marcus S, Yocum A, Chen T, Stefanos M, Druker B, Byrd JC. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020 12; 26(12):1852-1858. PMID: 33106665; PMCID: PMC8530434.
      Citations: 106     Fields:    Translation:HumansCTClinical Trials
    144. Loh KP, Abdallah M, Kadambi S, Wells M, Kumar AJ, Mendler JH, Liesveld JL, Wittink M, O'Dwyer K, Becker MW, McHugh C, Stock W, Majhail NS, Wildes TM, Duberstein P, Mohile SG, Klepin HD. Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists. Leuk Lymphoma. 2021 02; 62(2):387-398. PMID: 33040623; PMCID: PMC7878016.
      Citations: 21     Fields:    Translation:Humans
    145. Rank CU, Lynggaard LS, Als-Nielsen B, Stock W, Toft N, Nielsen OJ, Frandsen TL, Tuckuviene R, Schmiegelow K. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. Cochrane Database Syst Rev. 2020 10 10; 10:CD013399. PMID: 33038027; PMCID: PMC9831116.
      Citations: 12     Fields:    Translation:Humans
    146. Flannelly C, Tan BE, Tan JL, McHugh CM, Sanapala C, Lagu T, Liesveld JL, Aljitawi O, Becker MW, Mendler JH, Klepin HD, Stock W, Wildes TM, Artz A, Majhail NS, Loh KP. Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age. Biol Blood Marrow Transplant. 2020 12; 26(12):2335-2345. PMID: 32961375; PMCID: PMC7686105.
      Citations: 28     Fields:    Translation:Humans
    147. Cassaday RD, Marks DI, DeAngelo DJ, Jabbour EJ, Advani AS, O'Brien S, Wang T, Neuhof A, Vandendries E, Kantarjian HM, Stock W, Stelljes M. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. Br J Haematol. 2020 11; 191(3):e77-e81. PMID: 32805058.
      Citations: 6     Fields:    Translation:Humans
    148. DeAngelo DJ, Advani AS, Marks DI, Liedtke M, Stock W, Jabbour E, Merchant A, Wang T, Vandendries E, Neuhof A, Kantarjian H, O'Brien S, Stelljes M, Gökbuget N. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020 08 07; 10(8):81. PMID: 32769965; PMCID: PMC7414105.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    149. Stock W. Thrombosis in ALL: a risk without clear mitigation. Blood. 2020 07 16; 136(3):264-265. PMID: 32673388.
      Citations: 1     Fields:    Translation:Humans
    150. Curran E, Stock W. Editorial. Semin Hematol. 2020 07; 57(3):101. PMID: 33256898.
      Citations:    Fields:    
    151. Goldberg AD, Atallah E, Rizzieri D, Walter RB, Chung KY, Spira A, Stock W, Tallman MS, Cruz HG, Boni J, Havenith KEG, Chao G, Feingold JM, Wuerthner J, Solh M. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Leuk Res. 2020 08; 95:106385. PMID: 32521310.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    152. Patel AA, Thomas J, Rojek AE, Stock W. Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults. Curr Treat Options Oncol. 2020 05 28; 21(7):57. PMID: 32468488.
      Citations: 27     Fields:    Translation:Humans
    153. Christian S, Arain S, Patel P, Khan I, Calip GS, Agrawal V, Sweiss K, Griffin S, Cahill K, Konig H, Esen A, Shergill A, Odenike O, Stock W, Quigley JG. A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2020 08; 95(8):937-943. PMID: 32311140; PMCID: PMC9150866.
      Citations: 3     Fields:    Translation:Humans
    154. Jabbour E, Advani AS, DeAngelo DJ, Marks DI, Stock W, O'Brien S, Cassaday RD, Wang T, Neuhof A, Vandendries E, Kantarjian H, Stelljes M, Gökbuget N. Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. Leuk Lymphoma. 2020 08; 61(8):2012-2015. PMID: 32378440.
      Citations: 7     Fields:    Translation:Humans
    155. Cooperrider JH, Fulton N, Artz AS, Larson RA, Stock W, Kosuri S, Bishop M, Liu H. Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2020 11; 55(11):2204-2206. PMID: 32376970.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    156. Patel AA, Cahill K, Charnot-Katsikas A, Liu H, Gurbuxani S, Thirman M, Kosuri S, Artz AS, Larson RA, Stock W, Segal J, Odenike O. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51. PMID: 32358888.
      Citations: 18     Fields:    Translation:Humans
    157. Kaplan LD, Maurer MJ, Stock W, Bartlett NL, Fulton N, Pettinger A, Byrd JC, Blum KA, LaCasce AS, Hsi ED, Liu YT, Scott DW, Hurd D, Ruppert AS, Hernandez-Ilizaliturri F, Leonard JP, Cheson BD. Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. Am J Hematol. 2020 06; 95(6):583-593. PMID: 32170769; PMCID: PMC7486983.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    158. Autry RJ, Paugh SW, Carter R, Shi L, Liu J, Ferguson DC, Lau CE, Bonten EJ, Yang W, McCorkle JR, Beard JA, Panetta JC, Diedrich JD, Crews KR, Pei D, Coke CJ, Natarajan S, Khatamian A, Karol SE, Lopez-Lopez E, Diouf B, Smith C, Gocho Y, Hagiwara K, Roberts KG, Pounds S, Kornblau SM, Stock W, Paietta EM, Litzow MR, Inaba H, Mullighan CG, Jeha S, Pui CH, Cheng C, Savic D, Yu J, Gawad C, Relling MV, Yang JJ, Evans WE. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nat Cancer. 2020 03; 1(3):329-344. PMID: 32885175; PMCID: PMC7467080.
      Citations: 44     Fields:    Translation:HumansAnimals
    159. King AA, Vesely SK, Vettese E, Cook S, Cuker A, Stock W, Homer M, Fritz J, Sung L. Impact of gender and caregiving responsibilities on academic success in hematology. Blood Adv. 2020 02 25; 4(4):755-761. PMID: 32097459; PMCID: PMC7042991.
      Citations: 8     Fields:    Translation:Humans
    160. Marcucci G, Geyer S, Laumann K, Zhao W, Bucci D, Uy GL, Blum W, Eisfeld AK, Pardee TS, Wang ES, Stock W, Kolitz JE, Kohlschmidt J, Bloomfield CD, Stone RM, Larson RA, Mrózek K. Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Adv. 2020 02 25; 4(4):696-705. PMID: 32092139; PMCID: PMC7042984.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    161. Cahill KE, Karimi YH, Karrison TG, Jain N, Green M, Weiner H, Fulton N, Kadri S, Godley LA, Artz AS, Liu H, Thirman MJ, Le Beau MM, McNerney ME, Segal J, Larson RA, Stock W, Odenike O. A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020 02 25; 4(4):599-606. PMID: 32074275; PMCID: PMC7042987.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    162. Suh E, Stratton KL, Leisenring WM, Nathan PC, Ford JS, Freyer DR, McNeer JL, Stock W, Stovall M, Krull KR, Sklar CA, Neglia JP, Armstrong GT, Oeffinger KC, Robison LL, Henderson TO. Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study. Lancet Oncol. 2020 03; 21(3):421-435. PMID: 32066543; PMCID: PMC7392388.
      Citations: 179     Fields:    Translation:Humans
    163. Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, Tomlinson B, Bhatnagar B, Feingold J, Ungar D, Chao G, Zhang X, Qin Y, Havenith K, Kantarjian H, Wieduwilt MJ. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Adv. 2020 02 11; 4(3):449-457. PMID: 32012214; PMCID: PMC7013258.
      Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
    164. Wang AY, Kline J, Stock W, Kosuri S, Artz A, Larson RA, Riedell PA, Bishop M, Liu H. Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 05; 26(5):1025-1027. PMID: 32018063.
      Citations: 20     Fields:    Translation:Humans
    165. Wang AY, Muffly LS, Stock W. Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults. JCO Oncol Pract. 2020 05; 16(5):231-238. PMID: 32048928.
      Citations: 3     Fields:    Translation:HumansCells
    166. Kothari S, Artz AS, Lee SM, Fulton N, Park JH, Stock W, Larson RA, Odenike O, Kline J, LaBelle J, Kosuri S, Riedell P, Nakamura Y, Bishop MR, Liu H. Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. Bone Marrow Transplant. 2020 06; 55(6):1161-1168. PMID: 31992847.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    167. Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, Stock W, Larson RA, Levine RL, Tallman MS, Park JH, Kerr C, Przychodzen B, Sekeres MA, Kalaycio ME, Carraway HE, Hamilton BK, Sobecks R, Gerds A, Mukherjee S, Nazha A, Maciejewski JP, Advani AS. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019 12 23; 3(24):4228-4237. PMID: 31869410; PMCID: PMC6929388.
      Citations: 25     Fields:    Translation:Humans
    168. Derman BA, Kordas K, Ridgeway J, Chow S, Dale W, Lee SM, Aguada E, Jakubowiak AJ, Jasielec J, Kline J, Kosuri S, Larson RA, Liu H, Mortel M, Odenike O, Pisano J, Riedell P, Stock W, Bishop MR, Artz AS. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019 11 26; 3(22):3488-3498. PMID: 31725894; PMCID: PMC6880895.
      Citations: 45     Fields:    Translation:Humans
    169. Jabbour E, Advani A, Stock W, Liedtke M, Martinelli G, O'Brien S, Wang T, Laird AD, Vandendries E, Neuhof A, Nguyen K, Dakappagari N, DeAngelo DJ, Kantarjian H, Gökbuget N, Stelljes M. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res. 2020 01; 88:106283. PMID: 31790983.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    170. Derman BA, Streck M, Wynne J, Christ TN, Curran E, Stock W, Knoebel RW. Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2020 03; 61(3):614-622. PMID: 31680584; PMCID: PMC7028458.
      Citations: 20     Fields:    Translation:HumansCells
    171. Balagopal V, Hantel A, Kadri S, Steinhardt G, Zhen CJ, Kang W, Wanjari P, Ritterhouse LL, Stock W, Segal JP. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. PLoS One. 2019; 14(10):e0224097. PMID: 31658273; PMCID: PMC6816574.
      Citations: 11     Fields:    Translation:HumansCells
    172. Klepin HD, Ritchie E, Major-Elechi B, Le-Rademacher J, Seisler D, Storrick L, Sanford BL, Marcucci G, Zhao W, Geyer SA, Ballman KV, Powell BL, Baer MR, Stock W, Cohen HJ, Stone RM, Larson RA, Uy GL. Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). J Geriatr Oncol. 2020 01; 11(1):107-113. PMID: 31668825; PMCID: PMC6943189.
      Citations: 28     Fields:    Translation:Humans
    173. DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, Rowe JM, Seftel MD, Stock W, Tallman MS, Fanning S, Inamoto Y, Kansagra A, Johnston L, Nagler A, Sauter CS, Savani BN, Perales MA, Carpenter PA, Larson RA, Weisdorf D. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019 11; 25(11):2113-2123. PMID: 31446198.
      Citations: 44     Fields:    Translation:Humans
    174. van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Gergis U, Shore T, Liu H, Rondon G, Mayer SA, Srour SA, Stock W, Ciurea SO. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019 06 25; 3(12):1858-1867. PMID: 31217161; PMCID: PMC6595267.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    175. Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019 Jun; 6(6):e317-e327. PMID: 31060979; PMCID: PMC9012213.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    176. Marks DI, Kebriaei P, Kantarjian H, Advani AS, Merchant A, Stock W, Cassaday RD, Wang T, Zhang H, Loberiza F, Vandendries E, DeAngelo DJ, Stelljes M, Gökbuget N. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2019 09; 25(9):1720-1729. PMID: 31039409.
      Citations: 34     Fields:    Translation:Humans
    177. Kantarjian HM, DeAngelo DJ, Liedtke M, Stock W, O'Brien SM, Jabbour E, Wang T, Liang White J, Sleight B, Vandendries E, Advani AS, Stelljes M, Gökbuget N. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019 07 15; 125(14):2474-2487. PMID: 30920645; PMCID: PMC6618133.
      Citations: 170     Fields:    Translation:HumansCTClinical Trials
    178. Ragon BK, Odenike O, Baer MR, Stock W, Borthakur G, Patel K, Han L, Chen H, Ma H, Joseph L, Zhao Y, Baggerly K, Konopleva M, Jain N. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk. 2019 07; 19(7):431-440.e13. PMID: 31056348; PMCID: PMC6626580.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    179. Curran E, Stock W. Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL. Blood. 2019 04 18; 133(16):1715-1719. PMID: 30796026; PMCID: PMC6634959.
      Citations: 34     Fields:    Translation:Humans
    180. Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA, Mrózek K. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 04 04; 133(14):1548-1559. PMID: 30658992; PMCID: PMC6450431.
      Citations: 213     Fields:    Translation:HumansCellsCTClinical Trials
    181. Jabbour E, Advani AS, Stelljes M, Stock W, Liedtke M, O'Brien S, White JL, Wang T, Luisa Paccagnella M, Sleight B, Vandendries E, DeAngelo DJ, Kantarjian HM, Gökbuget N, Martinelli G. Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. Am J Hematol. 2019 04; 94(4):408-416. PMID: 30623490.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    182. Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Newman S, Devidas M, Dai Y, Reshmi SC, Gastier-Foster J, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Racevskis J, Zhang Y, Bhatia R, Kohlschmidt J, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Evans WE, Jeha S, Pui CH, Yang J, Paietta E, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CG, Mrózek K. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019 02; 51(2):296-307. PMID: 30643249; PMCID: PMC6525306.
      Citations: 329     Fields:    Translation:HumansAnimalsCells
    183. Wynne J, Wright D, Stock W. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 01 08; 3(1):96-104. PMID: 30622147; PMCID: PMC6325303.
      Citations: 36     Fields:    Translation:HumansAnimals
    184. Fan Y, Artz AS, van Besien K, Stock W, Larson RA, Odenike O, Godley LA, Kline J, Cunningham JM, LaBelle JL, Bishop MR, Liu H. Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. Exp Hematol Oncol. 2019; 8:1. PMID: 30622841; PMCID: PMC6317199.
      Citations: 6     
    185. Roboz GJ, Mandrekar SJ, Desai P, Laumann K, Walker AR, Wang ES, Kolitz JE, Powell BL, Attar EC, Stock W, Bloomfield CD, Kohlschmidt J, Hassane DC, Garraway L, Baltay M, Tracy A, Marcucci G, Stone RM, Larson RA, Mrózek K, Jané-Valbuena J. Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv. 2018 12 26; 2(24):3608-3617. PMID: 30567725; PMCID: PMC6306886.
      Citations: 40     Fields:    Translation:Humans
    186. Kutny MA, Geyer S, Laumann KM, Gregory J, Willman CL, Stock W, Larson RA, Powell BL, Feusner JH. Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). Pediatr Blood Cancer. 2019 03; 66(3):e27542. PMID: 30393935; PMCID: PMC6392047.
      Citations: 8     Fields:    Translation:Humans
    187. Osman AEG, Anderson J, Churpek JE, Christ TN, Curran E, Godley LA, Liu H, Thirman MJ, Odenike T, Stock W, Larson RA. Treatment of Acute Promyelocytic Leukemia in Adults. J Oncol Pract. 2018 11; 14(11):649-657. PMID: 30423270.
      Citations: 29     Fields:    Translation:Humans
    188. Rank CU, Stock W. Should immunologic strategies be incorporated into frontline ALL therapy? Best Pract Res Clin Haematol. 2018 12; 31(4):367-372. PMID: 30466749.
      Citations: 1     Fields:    Translation:Humans
    189. Siegel SE, Advani A, Seibel N, Muffly L, Stock W, Luger S, Shah B, DeAngelo DJ, Freyer DR, Douer D, Johnson RH, Hayes-Lattin B, Lewis M, Jaboin JJ, Coccia PF, Bleyer A. Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens. Am J Hematol. 2018 10; 93(10):1254-1266. PMID: 30058716; PMCID: PMC7521142.
      Citations: 23     Fields:    Translation:Humans
    190. D'Angelo CR, Novitsky B, Mee Lee S, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Stock W, Bishop MR, Artz AS. Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2019 03; 60(3):629-638. PMID: 30070150.
      Citations: 2     Fields:    Translation:Humans
    191. Hantel A, Stock W, Kosuri S. Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):636-647. PMID: 30006258.
      Citations: 5     Fields:    Translation:Humans
    192. Wassermann T, Reimer EK, McKinnon M, Stock W. Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole. Antimicrob Agents Chemother. 2018 07; 62(7). PMID: 29661880; PMCID: PMC6021675.
      Citations: 6     Fields:    Translation:Humans
    193. Siegel SE, Stock W, Johnson RH, Advani A, Muffly L, Douer D, Reed D, Lewis M, Freyer DR, Shah B, Luger S, Hayes-Lattin B, Jaboin JJ, Coccia PF, DeAngelo DJ, Seibel N, Bleyer A. Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review. JAMA Oncol. 2018 05 01; 4(5):725-734. PMID: 29450465; PMCID: PMC7534395.
      Citations: 83     Fields:    Translation:Humans
    194. Wynne J, Stock W. "Dar"-ing to target CD38 in T-ALL. Blood. 2018 03 01; 131(9):948-949. PMID: 29496700.
      Citations: 3     Fields:    Translation:HumansCells
    195. Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clin Cancer Res. 2018 05 15; 24(10):2294-2303. PMID: 29463550.
      Citations: 63     Fields:    Translation:HumansCellsCTClinical Trials
    196. Muffly LS, Reizine N, Stock W. Management of acute lymphoblastic leukemia in young adults. Clin Adv Hematol Oncol. 2018 Feb; 16(2):138-146. PMID: 29741514.
      Citations: 8     Fields:    Translation:Humans
    197. Jabbour EJ, DeAngelo DJ, Stock W, Liedtke M, O'Brien S, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS, Kantarjian HM, Stelljes M, Gökbuget N. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018 04 15; 124(8):1722-1732. PMID: 29381191.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    198. Kebriaei P, Cutler C, de Lima M, Giralt S, Lee SJ, Marks D, Merchant A, Stock W, van Besien K, Stelljes M. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018 04; 53(4):449-456. PMID: 29330398; PMCID: PMC5897380.
      Citations: 66     Fields:    Translation:Humans
    199. Liu H, Zha Y, Choudhury N, Malnassy G, Fulton N, Green M, Park JH, Nakamura Y, Larson RA, Salazar AM, Odenike O, Gajewski TF, Stock W. WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. Exp Hematol Oncol. 2018; 7:1. PMID: 29344432; PMCID: PMC5765712.
      Citations: 13     
    200. Wang AY, Weiner H, Green M, Chang H, Fulton N, Larson RA, Odenike O, Artz AS, Bishop MR, Godley LA, Thirman MJ, Kosuri S, Churpek JE, Curran E, Pettit K, Stock W, Liu H. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 2018 01 05; 11(1):4. PMID: 29304833; PMCID: PMC5756334.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    201. Tsai SB, Rhodes J, Liu H, Shore T, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004. PMID: 29288821.
      Citations: 7     Fields:    Translation:Humans
    202. Leonard J, Stock W. Progress in adult ALL: incorporation of new agents to frontline treatment. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):28-36. PMID: 29222234; PMCID: PMC6142560.
      Citations: 7     Fields:    Translation:Humans
    203. Roboz GJ, Kantarjian HM, Yee KWL, Kropf PL, O'Connell CL, Griffiths EA, Stock W, Daver NG, Jabbour E, Ritchie EK, Walsh KJ, Rizzieri D, Lunin SD, Curio T, Chung W, Hao Y, Lowder JN, Azab M, Issa JJ. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 2018 01 15; 124(2):325-334. PMID: 29211308; PMCID: PMC5814873.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    204. Hsu J, Artz A, Mayer SA, Guarner D, Bishop MR, Reich-Slotky R, Smith SM, Greenberg J, Kline J, Ferrante R, Phillips AA, Gergis U, Liu H, Stock W, Cushing M, Shore TB, van Besien K. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018 02; 24(2):359-365. PMID: 29128555; PMCID: PMC6574086.
      Citations: 7     Fields:    Translation:Humans
    205. Chen LW, McShane PJ, Karkowsky W, Gray SE, Adegunsoye A, Stock W, Artz A, White SR, Montner SM, Strek ME. De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy. Chest. 2017 09; 152(3):683-685. PMID: 28889888; PMCID: PMC6026234.
      Citations: 9     Fields:    Translation:Humans
    206. Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ, Tibes R. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017 10; 18(10):1317-1326. PMID: 28844816; PMCID: PMC5925750.
      Citations: 84     Fields:    Translation:HumansCTClinical Trials
    207. DeAngelo DJ, Stock W, Stein AS, Shustov A, Liedtke M, Schiffer CA, Vandendries E, Liau K, Ananthakrishnan R, Boni J, Laird AD, Fostvedt L, Kantarjian HM, Advani AS. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017 Jun 27; 1(15):1167-1180. PMID: 29296758; PMCID: PMC5728308.
      Citations: 68     Fields:    
    208. Kadri S, Lee J, Fitzpatrick C, Galanina N, Sukhanova M, Venkataraman G, Sharma S, Long B, Petras K, Theissen M, Ming M, Kobzev Y, Kang W, Guo A, Wang W, Niu N, Weiner H, Thirman M, Stock W, Smith SM, Nabhan C, Segal JP, Lu P, Wang YL. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv. 2017 May 09; 1(12):715-727. PMID: 29296715; PMCID: PMC5728051.
      Citations: 74     Fields:    
    209. Christ TN, Stock W, Knoebel RW. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J Oncol Pharm Pract. 2018 Jun; 24(4):299-308. PMID: 28355969.
      Citations: 27     Fields:    Translation:Humans
    210. Brunner AM, Stock W. Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML. Oncology (Williston Park). 2017 Mar 15; 31(3):190, 192. PMID: 28299756.
      Citations:    Fields:    Translation:Humans
    211. Khan N, Hantel A, Knoebel RW, Artz A, Larson RA, Godley LA, Thirman MJ, Liu H, Churpek JE, King D, Odenike O, Stock W. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-7. PMID: 28278716.
      Citations: 13     Fields:    Translation:Humans
    212. Wolfson J, Sun CL, Wyatt L, Stock W, Bhatia S. Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma. Leukemia. 2017 06; 31(6):1450-1453. PMID: 28218238; PMCID: PMC5462848.
      Citations: 14     Fields:    Translation:Humans
    213. Wolfson J, Sun CL, Wyatt L, Stock W, Bhatia S. Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome. Cancer Epidemiol Biomarkers Prev. 2017 03; 26(3):312-320. PMID: 28209594; PMCID: PMC5546404.
      Citations: 45     Fields:    Translation:HumansPHPublic Health
    214. Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, DeAngelo DJ, Stock W, Sanford B, Blum WG, Bloomfield CD, Stone RM, Larson RA. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv. 2017 Jan 24; 1(5):331-340. PMID: 29034366; PMCID: PMC5637402.
      Citations: 34     Fields:    
    215. Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med. 2016 11 24; 375(21):2023-2036. PMID: 27959731; PMCID: PMC5217532.
      Citations: 437     Fields:    Translation:HumansCTClinical Trials
    216. Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen IM, Pei D, Iacobucci I, Valentine M, Pounds SB, Shi L, Li Y, Zhang J, Cheng C, Rambaldi A, Tosi M, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Wiernik PH, Bhatia R, Aldoss I, Kohlschmidt J, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Mullighan CG, Mrózek K. High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol. 2017 Feb; 35(4):394-401. PMID: 27870571; PMCID: PMC5455698.
      Citations: 209     Fields:    Translation:Humans
    217. Yap KL, Furtado LV, Kiyotani K, Curran E, Stock W, McNeer JL, Kadri S, Segal JP, Nakamura Y, Le Beau MM, Gurbuxani S, Raca G. Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL). Leuk Lymphoma. 2017 04; 58(4):950-958. PMID: 27855558; PMCID: PMC6077981.
      Citations: 11     Fields:    Translation:HumansCells
    218. Stock W, Diouf B, Crews KR, Pei D, Cheng C, Laumann K, Mandrekar SJ, Luger S, Advani A, Stone RM, Larson RA, Evans WE. An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther. 2017 03; 101(3):391-395. PMID: 27618250; PMCID: PMC5320866.
      Citations: 32     Fields:    Translation:Humans
    219. Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I, Shao Y, Chen IM, Valentine M, Pei D, Mungall KL, Mungall AJ, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster JM, Devidas M, Dai Y, Wood B, Borowitz M, Larsen EE, Maloney K, Mattano LA, Angiolillo A, Salzer WL, Burke MJ, Gianni F, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh ML, Hunger SP, Mullighan CG, Mrózek K. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun. 2016 11 08; 7:13331. PMID: 27824051; PMCID: PMC5105166.
      Citations: 163     Fields:    Translation:HumansAnimalsCells
    220. Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman ML, Wu G, Li Y, Wei L, Iacobucci I, Liu Y, Qu C, Wen J, Edmonson M, Payne-Turner D, Kaufmann KB, Takayanagi SI, Wienholds E, Ntziachristos P, Bakogianni S, Wang J, Aifantis I, Roberts KG, Ma J, Song G, Easton J, Mulder HL, Chen X, Newman S, Ma X, Rusch M, Gupta P, Boggs K, Vadodaria B, Dalton J, Liu Y, Valentine ML, Ding L, Lu C, Fulton RS, Fulton L, Tabib Y, Ochoa K, Devidas M, Pei D, Cheng C, Yang J, Evans WE, Relling MV, Pui CH, Jeha S, Harvey RC, Chen IL, Willman CL, Marcucci G, Bloomfield CD, Kohlschmidt J, Paietta E, Tallman MS, Stock W, Foster MC, Racevskis J, Rowe JM, Luger S, Kornblau SM, Shurtleff SA, Raimondi SC, Mardis ER, Wilson RK, Dick JE, Hunger SP, Loh ML, Downing JR, Mullighan CG, Waanders E, Mrózek K, St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016 12; 48(12):1481-1489. PMID: 27776115; PMCID: PMC5144107.
      Citations: 188     Fields:    Translation:Humans
    221. Sharma S, Galanina N, Guo A, Lee J, Kadri S, Van Slambrouck C, Long B, Wang W, Ming M, Furtado LV, Segal JP, Stock W, Venkataraman G, Tang WJ, Lu P, Wang YL. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget. 2016 Oct 18; 7(42):68833-68841. PMID: 27626698; PMCID: PMC5356593.
      Citations: 50     Fields:    Translation:HumansCells
    222. Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA, Malnassy G, Ma T, Garg M, Ding LW, Sun QY, Chien W, Ikezoe T, Lill M, Biondi A, Larson RA, Powell BL, Chng WJ, Tien HF, Heuser M, Ganser A, Koren-Michowitz M, Kornblau SM, Kantarjian HM, Nowak D, Hofmann WK, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih LY, Mathews V, Koeffler HP, Lübbert M. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016 12; 30(12):2430. PMID: 27713533; PMCID: PMC7609306.
      Citations: 20     Fields:    
    223. Blum W, Sanford BL, Klisovic R, DeAngelo DJ, Uy G, Powell BL, Stock W, Baer MR, Kolitz JE, Wang ES, Hoke E, Kohlschmidt J, Bloomfield CD, Geyer S, Marcucci G, Stone RM, Larson RA, Alliance for Clinical Trials in Oncology, Mrózek K. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia. 2017 01; 31(1):34-39. PMID: 27624549; PMCID: PMC5214595.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    224. Muffly L, Lichtensztajn D, Shiraz P, McNeer J, Stock W, Keegan T, Gomez SL, Abrahão R. Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study. Cancer. 2017 Jan 01; 123(1):122-130. PMID: 27622953; PMCID: PMC5161602.
      Citations: 24     Fields:    Translation:Humans
    225. Leonard JT, Stock W. The Persistence of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: We Know It's Bad, Now What? Biol Blood Marrow Transplant. 2016 11; 22(11):1913-1914. PMID: 27634020.
      Citations: 1     Fields:    Translation:HumansCells
    226. Pettit K, Stock W, Walter RB. Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. Leuk Lymphoma. 2016 07; 57(7):1527-33. PMID: 27269126; PMCID: PMC4968046.
      Citations:    Fields:    Translation:Humans
    227. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Aug 25; 375(8):740-53. PMID: 27292104; PMCID: PMC5594743.
      Citations: 602     Fields:    Translation:HumansCTClinical Trials
    228. Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA, Malnassy G, Ma T, Garg M, Ding LW, Sun QY, Chien W, Ikezoe T, Lill M, Biondi A, Larson RA, Powell BL, Chng WJ, Tien HF, Heuser M, Ganser A, Koren-Michowitz M, Kornblau SM, Kantarjian HM, Nowak D, Hofmann WK, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih LY, Mathews V, Koeffler HP, Lübbert M. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016 08; 30(8):1672-81. PMID: 27063598; PMCID: PMC4972641.
      Citations: 58     Fields:    Translation:Humans
    229. Alachkar H, Fulton N, Sanford B, Malnassy G, Mutonga M, Larson RA, Bloomfield CD, Marcucci G, Nakamura Y, Stock W. Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics J. 2017 06; 17(3):274-279. PMID: 27019981; PMCID: PMC5089920.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    230. Tsai SB, Liu H, Shore T, Fan Y, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Martinez G, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS. Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2016 06; 22(6):1065-1072. PMID: 26912055; PMCID: PMC4867292.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    231. DeBoer R, Koval G, Mulkey F, Wetzler M, Devine S, Marcucci G, Stone RM, Larson RA, Bloomfield CD, Geyer S, Mullighan CG, Stock W. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma. 2016 10; 57(10):2298-306. PMID: 26892479; PMCID: PMC5008253.
      Citations: 24     Fields:    Translation:HumansCells
    232. van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, Odenike O, Larson R, Bishop M, Wickrema A, Gergis U, Mayer S, Shore T, Tsai S, Rhodes J, Cushing MM, Korman S, Artz A. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43. PMID: 26869630; PMCID: PMC5004373.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    233. Muffly LS, Hlubocky FJ, Khan N, Wroblewski K, Breitenbach K, Gomez J, McNeer JL, Stock W, Daugherty CK. Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship. Cancer. 2016 Mar 15; 122(6):954-61. PMID: 26749023.
      Citations: 26     Fields:    Translation:Humans
    234. D'Angelo CR, Kocherginsky M, Pisano J, Bishop MR, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Stock W, Artz AS. Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. Leuk Lymphoma. 2016 08; 57(8):1807-13. PMID: 26699199.
      Citations: 11     Fields:    Translation:HumansCells
    235. Alachkar H, Mutonga M, Malnassy G, Park JH, Fulton N, Woods A, Meng L, Kline J, Raca G, Odenike O, Takamatsu N, Miyamoto T, Matsuo Y, Stock W, Nakamura Y. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. Oncotarget. 2015 Oct 20; 6(32):33410-25. PMID: 26450903; PMCID: PMC4741775.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    236. Mutonga M, Tamura K, Malnassy G, Fulton N, de Albuquerque A, Hamamoto R, Stock W, Nakamura Y, Alachkar H. Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL). Transl Oncol. 2015 Oct; 8(5):368-375. PMID: 26500027; PMCID: PMC4631083.
      Citations: 14     
    237. Uy GL, Hsu YM, Schmidt AP, Stock W, Fletcher TR, Trinkaus KM, Westervelt P, DiPersio JF, Link DC. Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. Leuk Res. 2015 Dec; 39(12):1437-42. PMID: 26467815; PMCID: PMC4661095.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    238. Papayannidis C, DeAngelo DJ, Stock W, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, Ozeck M, Aster JC, Kuo F, Huang D, Lira PD, McLachlan KR, Kern KA, Garcia-Manero G, Martinelli G. A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J. 2015 Sep 25; 5:e350. PMID: 26407235; PMCID: PMC4648526.
      Citations: 72     Fields:    Translation:HumansCTClinical Trials
    239. Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep; 16(9):1099-1110. PMID: 26296954; PMCID: PMC5557041.
      Citations: 139     Fields:    Translation:HumansCTClinical Trials
    240. Flowers CR, Brown JR, Rosenthal H, Stock W, Katzen HI, Cohen JB, Sinha R, Lakhanpal S, Leis JF, Waller EK, Jaye DL. A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):694-8. PMID: 26385641.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    241. Stock W. Novel drug targets in acute leukemia. Clin Adv Hematol Oncol. 2015 Aug; 13(8):493-5. PMID: 26351809.
      Citations:    Fields:    Translation:Humans
    242. Liu H, Stock W. Is it time to use minimal residual disease to stratify post-remission treatment for acute myeloid leukemia? Leuk Lymphoma. 2015; 56(11):3005-7. PMID: 25944470.
      Citations: 1     Fields:    Translation:Humans
    243. Yew PY, Alachkar H, Yamaguchi R, Kiyotani K, Fang H, Yap KL, Liu HT, Wickrema A, Artz A, van Besien K, Imoto S, Miyano S, Bishop MR, Stock W, Nakamura Y. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015 Sep; 50(9):1227-34. PMID: 26052909; PMCID: PMC4559843.
      Citations: 74     Fields:    Translation:HumansCellsCTClinical Trials
    244. Kayser S, Walter RB, Stock W, Schlenk RF. Minimal residual disease in acute myeloid leukemia--current status and future perspectives. Curr Hematol Malig Rep. 2015 Jun; 10(2):132-44. PMID: 25994952.
      Citations: 17     Fields:    Translation:Humans
    245. Weiss AR, Hayes-Lattin B, Kutny MA, Stock W, Stegenga K, Freyer DR. Inclusion of Adolescents and Young Adults in Cancer Clinical Trials. Semin Oncol Nurs. 2015 Aug; 31(3):197-205. PMID: 26210198; PMCID: PMC5520996.
      Citations: 10     Fields:    Translation:Humans
    246. Curran E, Stock W. How I treat acute lymphoblastic leukemia in older adolescents and young adults. Blood. 2015 Jun 11; 125(24):3702-10. PMID: 25805810; PMCID: PMC4463735.
      Citations: 66     Fields:    Translation:Humans
    247. Li Z, Onel K, Sukhanova M, Mirza MK, Yap KL, Borinets O, Larson RA, Stock W, Sasaki MM, Joseph L, Raca G, Stölzel F. Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma. Leukemia. 2015 Oct; 29(10):2113-6. PMID: 25787914; PMCID: PMC4575593.
      Citations: 17     Fields:    Translation:Humans
    248. Alachkar H, Mutonga MB, Fulton N, Malnassy G, Bohlander SK, Matsuo Y, Stock W, Nakamura Y, Metzeler KH, Herold T, Spiekermann K, Hiddemann W. Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia. Oncotarget. 2014 Dec 15; 5(23):12371-82. PMID: 25365263; PMCID: PMC4323011.
      Citations: 40     Fields:    Translation:HumansCells
    249. Odenike O, Halpern A, Godley LA, Madzo J, Karrison T, Green M, Fulton N, Mattison RJ, Yee KW, Bennett M, Koval G, Malnassy G, Larson RA, Ratain MJ, Stock W. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9. PMID: 25483416; PMCID: PMC4390421.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    250. Perez-Andreu V, Roberts KG, Xu H, Smith C, Zhang H, Yang W, Harvey RC, Payne-Turner D, Devidas M, Cheng IM, Carroll WL, Heerema NA, Carroll AJ, Raetz EA, Gastier-Foster JM, Marcucci G, Bloomfield CD, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Rowe JM, Luger SM, Tallman MS, Dean M, Burchard EG, Torgerson DG, Yue F, Wang Y, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Loh ML, Willman CL, Hunger SP, Mullighan CG, Yang JJ, Mrózek K. A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood. 2015 Jan 22; 125(4):680-6. PMID: 25468567; PMCID: PMC4304112.
      Citations: 62     Fields:    Translation:HumansCells
    251. Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2015 Mar; 168(6):796-805. PMID: 25403830; PMCID: PMC4354261.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    252. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG, Mrózek K. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014 Sep 11; 371(11):1005-15. PMID: 25207766; PMCID: PMC4191900.
      Citations: 719     Fields:    Translation:HumansAnimalsCells
    253. Raca G, Gurbuxani S, Zhang Z, Li Z, Sukhanova M, McNeer J, Stock W. RCSD1-ABL2 fusion resulting from a complex chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2015 Apr; 56(4):1145-7. PMID: 25098428.
      Citations: 3     Fields:    Translation:HumansCells
    254. Petri CR, O'Donnell PH, Cao H, Artz AS, Stock W, Wickrema A, Hard M, van Besien K. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma. 2014 Dec; 55(12):2866-73. PMID: 24564572; PMCID: PMC4477686.
      Citations: 12     Fields:    Translation:Humans
    255. Mirza MK, Sukhanova M, Onel K, Larson RA, Stock W, Ehninger G, Kuithan F, Reddy P, Joseph L, Raca G, Stölzel F, Zöphel K. Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays. Leuk Res. 2014 Sep; 38(9):1091-6. PMID: 25088808; PMCID: PMC4157130.
      Citations: 5     Fields:    Translation:Humans
    256. Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike OM, Larson RA, van Besien K, Artz AS. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 Aug; 99(8):1373-9. PMID: 24816237; PMCID: PMC4116837.
      Citations: 123     Fields:    Translation:Humans
    257. Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Zuber J, Lowe SW, Kogan S. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell. 2014 May 12; 25(5):652-65. PMID: 24794707; PMCID: PMC4206212.
      Citations: 198     Fields:    Translation:HumansAnimalsCells
    258. Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol. 2014 May; 165(4):497-503. PMID: 24528179; PMCID: PMC4064464.
      Citations: 18     Fields:    Translation:HumansAnimals
    259. Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA, Tallman MS, Appelbaum FR, Sher D, Willman C, Paietta E, Stock W, Poiré X. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014 Jul; 55(7):1523-32. PMID: 24160850; PMCID: PMC4273565.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    260. Kim TW, Liu W, Myers JL, Mirkov S, Owzar K, Watson D, Mulkey F, Gamazon ER, Stock W, Undevia S, Innocenti F, Ratain MJ, Ramírez J. A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics. 2014 Feb; 24(2):129-32. PMID: 24300566; PMCID: PMC3901533.
      Citations: 2     Fields:    Translation:Humans
    261. Kolitz JE, George SL, Benson DM, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri MA, Larson RA, Alliance for Clinical Trials in Oncology. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer. 2014 Apr 01; 120(7):1010-7. PMID: 24382782; PMCID: PMC4139069.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    262. Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA, Lipton JH, Slovak ML, Appelbaum FR, Druker BJ. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol. 2014 Jan; 164(2):223-32. PMID: 24383843; PMCID: PMC4127316.
      Citations: 34     Fields:    Translation:HumansCellsCTClinical Trials
    263. Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8. PMID: 24178622; PMCID: PMC4310865.
      Citations: 76     Fields:    Translation:HumansCTClinical Trials
    264. Wetzler M, Watson D, Stock W, Koval G, Mulkey FA, Hoke EE, McCarty JM, Blum WG, Powell BL, Marcucci G, Bloomfield CD, Linker CA, Larson RA. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 2014 Jan; 99(1):111-5. PMID: 24077846; PMCID: PMC4007937.
      Citations: 41     Fields:    Translation:Humans
    265. Locke F, Agarwal R, Kunnavakkam R, van Besien K, Larson RA, Odenike O, Godley LA, Liu H, Le Beau MM, Gurbuxani S, Thirman MJ, Sipkins D, White C, Artz A, Stock W. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013 Nov; 48(11):1437-43. PMID: 23771005; PMCID: PMC4279870.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    266. Jain N, Liu H, Artz AS, Anastasi J, Odenike O, Godley LA, Joseph L, Marino S, Kline J, Nguyen V, Schouten V, Kunnavakkam R, Larson RA, Stock W, Ulaszek J, Savage PA, Wickrema A, van Besien K. Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leuk Lymphoma. 2013 Jun; 54(6):1242-9. PMID: 23088744.
      Citations: 11     Fields:    Translation:HumansCells
    267. Liu H, Stock W, Bishop MR. Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies. Curr Opin Hematol. 2013 Mar; 20(2):115-22. PMID: 23385613.
      Citations: 8     Fields:    Translation:Humans
    268. Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, Payne-Turner D, Churchman M, Andersson A, Chen SC, McCastlain K, Becksfort J, Ma J, Wu G, Patel SN, Heatley SL, Phillips LA, Song G, Easton J, Parker M, Chen X, Rusch M, Boggs K, Vadodaria B, Hedlund E, Drenberg C, Baker S, Pei D, Cheng C, Huether R, Lu C, Fulton RS, Fulton LL, Tabib Y, Dooling DJ, Ochoa K, Minden M, Lewis ID, To LB, Marlton P, Roberts AW, Raca G, Stock W, Neale G, Drexler HG, Dickins RA, Ellison DW, Shurtleff SA, Pui CH, Ribeiro RC, Devidas M, Carroll AJ, Heerema NA, Wood B, Borowitz MJ, Gastier-Foster JM, Raimondi SC, Mardis ER, Wilson RK, Downing JR, Hunger SP, Loh ML, Mullighan CG. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013 Mar; 45(3):242-52. PMID: 23334668; PMCID: PMC3919793.
      Citations: 362     Fields:    Translation:HumansAnimalsCells
    269. O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, Heffner LT, Larson M, Seiter K, Smith S, Assouline S, Kuriakose P, Maness L, Nagler A, Rowe J, Schaich M, Shpilberg O, Yee K, Schmieder G, Silverman JA, Thomas D, Deitcher SR, Kantarjian H. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013 Feb 20; 31(6):676-83. PMID: 23169518; PMCID: PMC4979201.
      Citations: 67     Fields:    Translation:HumansCellsCTClinical Trials
    270. Van Besien K, Liu H, Jain N, Stock W, Artz A. Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant. 2013 May; 19(5):682-91. PMID: 23142329; PMCID: PMC3618995.
      Citations: 16     Fields:    Translation:Humans
    271. Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov; 13(11):1096-104. PMID: 23075701; PMCID: PMC4004358.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    272. Bleyer A, Siegel SE, Coccia PF, Stock W, Seibel NL. Children, adolescents, and young adults with leukemia: the empty half of the glass is growing. J Clin Oncol. 2012 Nov 10; 30(32):4037-8; author reply 4038-9. PMID: 23032621.
      Citations: 6     Fields:    Translation:Humans
    273. Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012 Nov 08; 120(19):3898-905. PMID: 22915637; PMCID: PMC3496952.
      Citations: 80     Fields:    Translation:HumansCTClinical Trials
    274. Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, DeAngelo DJ, Vardiman JW, McDonnell D, Bloomfield CD, Larson RA, Mrózek K. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013 Jan 01; 119(1):90-8. PMID: 22744771; PMCID: PMC4220742.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    275. Gallagher RE, Moser BK, Racevskis J, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D, Schachter-Tokarz E, Zhou DC, Chen IM, Harvey R, Koval G, Sher DA, Feusner JH, Tallman MS, Larson RA, Powell BL, Appelbaum FR, Paietta E, Willman CL, Stock W, Poiré X. Treatment-influenced associations of PML-RARa mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood. 2012 Sep 06; 120(10):2098-108. PMID: 22734072; PMCID: PMC3437597.
      Citations: 35     Fields:    Translation:Humans
    276. Richa EM, Kunnavakkam R, Godley LA, Kline J, Odenike O, Larson RA, Nguyen V, Stock W, Wickrema A, Van Besien K, Artz AS. Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy. 2012 Jul; 14(6):707-15. PMID: 22548695.
      Citations: 4     Fields:    Translation:Humans
    277. Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, Van Besien K, Larson RA, Stock W. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50. PMID: 21913806.
      Citations: 7     Fields:    Translation:Humans
    278. Wang ES, Yee K, Koh LP, Hogge D, Enschede S, Carlson DM, Dudley M, Glaser K, McKeegan E, Albert DH, Li X, Pradhan R, Stock W. Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. Leuk Lymphoma. 2012 Aug; 53(8):1543-51. PMID: 22280537.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    279. Kutny MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J, Larson RA, Powell BL, Stock W, Willman CL, Woods WG, Meshinchi S. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Oct; 59(4):662-7. PMID: 22378655; PMCID: PMC3368997.
      Citations: 26     Fields:    Translation:Humans
    280. Liu H, Johnson JL, Koval G, Malnassy G, Sher D, Damon LE, Hsi ED, Bucci DM, Linker CA, Cheson BD, Stock W. Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica. 2012 Apr; 97(4):579-85. PMID: 22102709; PMCID: PMC3347669.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    281. van Besien K, Stock W, Rich E, Odenike O, Godley LA, O'Donnell PH, Kline J, Nguyen V, Del Cerro P, Larson RA, Artz AS. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21. PMID: 22079470; PMCID: PMC3423318.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    282. Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, Kline J, Nguyen V, Cunningham J, Larson RA, del Cerro P, Schroeder L, Pape L, Stock W, Wickrema A, Artz AS, van Besien K. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011 Dec 08; 118(24):6438-45. PMID: 21976674; PMCID: PMC3236125.
      Citations: 72     Fields:    Translation:HumansCellsCTClinical Trials
    283. Breitenbach K, Stock W. Intergroup Trial C10403: A Pediatric Treatment Approach to Improve Outcomes in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. J Adolesc Young Adult Oncol. 2011 Jun; 1(2):107-8. PMID: 26812633.
      Citations: 6     Fields:    
    284. Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, Kovacsovics T, Litzow M, Rytting M, Borthakur G, Bleyer A. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011 Dec; 52(12):2237-53. PMID: 21827361.
      Citations: 94     Fields:    Translation:Humans
    285. Kantarjian HM, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, Altman JK, Minden M. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Invest New Drugs. 2012 Jun; 30(3):1107-15. PMID: 21494838; PMCID: PMC4205950.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    286. Odenike O, Thirman MJ, Artz AS, Godley LA, Larson RA, Stock W. Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol. 2011 Apr; 38(2):196-214. PMID: 21421110.
      Citations: 12     Fields:    Translation:Humans
    287. Godley LA, Cunningham J, Dolan ME, Huang RS, Gurbuxani S, McNerney ME, Larson RA, Leong H, Lussier Y, Onel K, Odenike O, Stock W, White KP, Le Beau MM. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24. PMID: 21421111; PMCID: PMC5591437.
      Citations: 5     Fields:    Translation:HumansCells
    288. Kenkre VP, Horowitz S, Artz AS, Liao C, Cohen KS, Godley LA, Kline JP, Smith SM, Stock W, van Besien K. T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma. 2011 Feb; 52(2):214-22. PMID: 21142785; PMCID: PMC3617078.
      Citations: 9     Fields:    Translation:Humans
    289. O'Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Van Besien K. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9. PMID: 20919852; PMCID: PMC4477684.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    290. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11; 116(19):3751-7. PMID: 20705755; PMCID: PMC2981533.
      Citations: 149     Fields:    Translation:Humans
    291. Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Marcucci G, Hurd D, Larson RA, Cancer and Leukemia Group B. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res. 2011 Mar; 35(3):329-33. PMID: 20688393; PMCID: PMC3023007.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    292. Bacher U, Bader P, Borowitz MJ, Dreger P, Khouri I, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS, Kröger N, Böttcher S. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant. 2010 Oct; 16(10):1325-46. PMID: 20637879.
      Citations: 12     Fields:    Translation:HumansPHPublic Health
    293. Bacher U, Bader P, Borowitz MJ, Dreger P, Khouri I, Macapinlac HA, Macapintac H, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS, Kröger N, Böttcher S. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1187-211. PMID: 20558311; PMCID: PMC7272718.
      Citations: 30     Fields:    Translation:Humans
    294. Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, DeAngelo DJ, Shea TC, Stock W, Baer MR, Hars V, Maharry K, Hoke E, Vardiman JW, Bloomfield CD, Larson RA, Cancer and Leukemia Group B. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010 Sep 02; 116(9):1413-21. PMID: 20522709; PMCID: PMC2938834.
      Citations: 64     Fields:    Translation:Humans
    295. Godley LA, Njiaju UO, Green M, Weiner H, Lin S, Odenike O, Rich ES, Artz A, Van Besien K, Daugherty CK, Zhang Y, Le Beau MM, Stock W, Larson RA. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma. 2010 Jun; 51(6):995-1006. PMID: 20536346.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    296. Locke FL, Artz A, Rich E, Zhang Y, van Besien K, Stock W. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant. 2010 Dec; 45(12):1692-8. PMID: 20208570.
      Citations: 11     Fields:    Translation:Humans
    297. Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, Kantarjian HM. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010 Mar 01; 116(5):1165-76. PMID: 20101737; PMCID: PMC5345568.
      Citations: 103     Fields:    Translation:HumansCells
    298. Stock W. Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma. 2010 Feb; 51(2):188-98. PMID: 20001232.
      Citations: 5     Fields:    Translation:Humans
    299. Slovak ML, Bedell V, Lew D, Albain KS, Ellis GK, Livingston RB, Martino S, Perez EA, Hortobagyi GN, Sher D, Stock W. Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012). Breast Cancer Res Treat. 2010 Jan; 119(2):391-8. PMID: 19851858; PMCID: PMC3024910.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    300. Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010; 2010:21-9. PMID: 21239766.
      Citations: 42     Fields:    Translation:Humans
    301. Thomas DA, Kantarjian HM, Stock W, Heffner LT, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Pierce S, Lu B, Deitcher SR, O'Brien S. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer. 2009 Dec 01; 115(23):5490-8. PMID: 19708032; PMCID: PMC4458381.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    302. Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC. A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma. 2009 Dec; 50(12):1958-63. PMID: 19860603; PMCID: PMC8166408.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    303. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20; 27(36):6101-8. PMID: 19917845; PMCID: PMC2793032.
      Citations: 70     Fields:    Translation:HumansCTClinical Trials
    304. van Besien K, Dew A, Lin S, Joseph L, Godley LA, Larson RA, Odenike T, Rich E, Stock W, Wickrema A, Artz AS. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17. PMID: 19821799.
      Citations: 26     Fields:    Translation:Humans
    305. Abutalib SA, Wetzler M, Stock W. Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009 Oct; 23(5):1099-119, vii. PMID: 19825455.
      Citations:    Fields:    Translation:Humans
    306. Wetzler M, Stock W. Preface: acute lymphoblastic leukemia--quo vadis? Hematol Oncol Clin North Am. 2009 Oct; 23(5):xi-xviii. PMID: 19825446.
      Citations: 1     Fields:    Translation:Humans
    307. Giles F, Vey N, DeAngelo D, Seiter K, Stock W, Stuart R, Boskovic D, Pigneux A, Tallman M, Brandwein J, Kell J, Robak T, Staib P, Thomas X, Cahill A, Albitar M, O'Brien S. Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood. 2009 Nov 05; 114(19):4027-33. PMID: 19710500.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    308. O'Donnell PH, Swanson K, Josephson MA, Artz AS, Parsad SD, Ramaprasad C, Pursell K, Rich E, Stock W, van Besien K. BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1038-1048.e1. PMID: 19660716; PMCID: PMC2723723.
      Citations: 31     Fields:    Translation:HumansCells
    309. Borrello IM, Levitsky HI, Stock W, Sher D, Qin L, DeAngelo DJ, Alyea EP, Stone RM, Damon LE, Linker CA, Maslyar DJ, Hege KM. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood. 2009 Aug 27; 114(9):1736-45. PMID: 19556425; PMCID: PMC2738565.
      Citations: 49     Fields:    Translation:HumansCellsCTClinical Trials
    310. Stock W. Clinical trials in adult AML. Clin Adv Hematol Oncol. 2009 Jun; 7(6):8-10. PMID: 19645130.
      Citations:    Fields:    Translation:Humans
    311. Stock W. Pediatric regimens for adult acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2009 Apr; 7(4):244-6. PMID: 19521325.
      Citations:    Fields:    Translation:Humans
    312. Kenkre VP, Stock W. Burkitt lymphoma/leukemia: improving prognosis. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S231-8. PMID: 19778846.
      Citations: 11     Fields:    Translation:Humans
    313. Artz A, Larson RA, Kline J, Odenike O, Rich E, Godley L, Stock W, van Besien K, Poiré X. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91. PMID: 19142796; PMCID: PMC3617055.
      Citations: 6     Fields:    Translation:Humans
    314. Odenike OM, Alkan S, Sher D, Godwin JE, Huo D, Brandt SJ, Green M, Xie J, Zhang Y, Vesole DH, Stiff P, Wright J, Larson RA, Stock W. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res. 2008 Nov 01; 14(21):7095-101. PMID: 18981008; PMCID: PMC4498482.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    315. Artz AS, Wickrema A, Dinner S, Godley LA, Kocherginsky M, Odenike O, Rich ES, Stock W, Ulaszek J, Larson RA, van Besien K. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1209-16. PMID: 18940674; PMCID: PMC2668514.
      Citations: 41     Fields:    Translation:Humans
    316. Dew A, Collins D, Artz A, Rich E, Stock W, Swanson K, van Besien K. Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options. Biol Blood Marrow Transplant. 2008 Aug; 14(8):938-41. PMID: 18640578; PMCID: PMC2556036.
      Citations: 25     Fields:    Translation:Humans
    317. Stone RM, Donohue KA, Stock W, Hars V, Linker CA, Shea T, Deangelo DJ, Marcucci G, Bloomfield CD, Larson RA, Cancer and Leukemia Group B. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol. 2009 Apr; 63(5):859-64. PMID: 18670778.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    318. Stock W. Advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2008 Jul; 6(7):487-8. PMID: 18654114.
      Citations: 3     Fields:    Translation:HumansCells
    319. Mattison R, Stock W. Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults. Curr Hematol Malig Rep. 2008 Jul; 3(3):144-51. PMID: 20425459.
      Citations: 1     Fields:    Translation:Humans
    320. Larson S, Stock W. Progress in the treatment of adults with acute lymphoblastic leukemia. Curr Opin Hematol. 2008 Jul; 15(4):400-7. PMID: 18536580.
      Citations: 15     Fields:    Translation:Humans
    321. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, Larson RA, Nachman J, Children's Cancer Group, Cancer and Leukemia Group B studies. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008 Sep 01; 112(5):1646-54. PMID: 18502832; PMCID: PMC2518876.
      Citations: 200     Fields:    Translation:HumansCTClinical Trials
    322. Odenike O, Green M, Larson RA, Rich ES, Ott J, Ratain MJ, Stock W. Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms. J Clin Oncol. 2008 May 20; 26(15_suppl):7057. PMID: 27949624.
      Citations:    
    323. Stock W, Najib K, Moser BK, Powell BL, Holowka N, Gulati K, Bloomfield CD, Larson RA, Sher D. High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): Correlation with diagnostic features and treatment outcome (CALGB 9710). J Clin Oncol. 2008 May 20; 26(15_suppl):7002. PMID: 27949960.
      Citations:    
    324. DeAngelo D, O'Brien SM, Vey N, Seiter K, Stock W, Cahill A, Pigneux A, Claxton D, Stuart R, Giles FJ. A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M in patients (pts) with first relapse of acute myeloid leukemia (AML). J Clin Oncol. 2008 May 20; 26(15_suppl):7051. PMID: 27949590.
      Citations:    
    325. Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2008 May 01; 14(9):2756-62. PMID: 18451242.
      Citations: 90     Fields:    Translation:HumansCTClinical Trials
    326. Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ, Giles FJ. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8. PMID: 18425419; PMCID: PMC4905709.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    327. Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van Laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, Marcucci G. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res. 2008 Apr 15; 14(8):2444-9. PMID: 18413836.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    328. Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock W. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7. PMID: 18297531.
      Citations: 2     Fields:    Translation:Humans
    329. Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney SM, Karrison TG, Ratain MJ, Stock W. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9. PMID: 18217206; PMCID: PMC4283497.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    330. Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM, Rich E, Smith SM, Zimmerman T, Zhang Y, Huo D, Larson R, van Besien K. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32. PMID: 17846595.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    331. Hill BT, Kondapalli L, Artz A, Smith S, Rich E, Godley L, Odenike O, Pursell KJ, Larson RA, Stock W, van Besien K. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leuk Lymphoma. 2007 Sep; 48(9):1799-805. PMID: 17786717.
      Citations: 5     Fields:    Translation:Humans
    332. Michaelis L, Lin S, Joseph L, Artz AS, Kline J, Pollyea D, Stock W, Rich E, Collins-Jones D, Casey B, Del Cerro P, van Besien K. Chimerism does not predict for outcome after alemtuzumab based conditioning. Bone Marrow Transplant. 2007 Jul; 40(2):181. PMID: 17502895.
      Citations:    Fields:    Translation:Humans
    333. Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O, Zimmerman T, Smith S, Godley L, Thirman M, Daugherty C, Extermann M, Larson R, van Besien K. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):954-64. PMID: 16920562.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    334. Moore J, Seiter K, Kolitz J, Stock W, Giles F, Kalaycio M, Zenk D, Marcucci G. A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res. 2006 Jul; 30(7):777-83. PMID: 16730060.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    335. Stock W, Yu D, Karrison T, Sher D, Stone RM, Larson RA, Bloomfield CD. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol. 2006 May; 28(5):1099-103. PMID: 16596225.
      Citations: 9     Fields:    Translation:HumansCells
    336. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM, Hehlmann R. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006 Jul 01; 108(1):28-37. PMID: 16522812; PMCID: PMC1895821.
      Citations: 370     Fields:    Translation:HumansCells
    337. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006 Feb 21; 103(8):2794-9. PMID: 16477019; PMCID: PMC1413797.
      Citations: 264     Fields:    Translation:Humans
    338. Kline J, Pollyea DA, Stock W, Artz A, Rich E, Godley L, Zimmerman T, Thompson K, Pursell K, Larson RA, van Besien K. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006 Feb; 37(3):307-10. PMID: 16400339.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    339. Stock W. Controversies in treatment of AML: case-based discussion. Hematology Am Soc Hematol Educ Program. 2006; 185-91. PMID: 17124059.
      Citations: 3     Fields:    Translation:Humans
    340. Wu D, Nair-Gill E, Sher DA, Parker LL, Campbell JM, Siddiqui M, Stock W, Kron SJ. Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads. Anal Biochem. 2005 Dec 01; 347(1):67-76. PMID: 16236241; PMCID: PMC4562293.
      Citations: 7     Fields:    Translation:AnimalsCells
    341. van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L, Jones D, Del Cerro P, Bennett D, Casey B, Odenike O, Thirman M, Daugherty C, Wickrema A, Zimmerman T, Larson RA, Stock W. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38. PMID: 16009946.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    342. Gore SD, Smith BD, Gojo I, Grever M, Kaufmann SH, Letendre L, Leonard DG, Marcucci G, Miller CB, Morris L, Piantadosi S, Prior T, Stock W, Karp JE. Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia. Am J Hematol. 2005 Jun; 79(2):119-27. PMID: 15929100.
      Citations: 2     Fields:    Translation:Humans
    343. Kebriaei P, Kline J, Stock W, Kasza K, Le Beau MM, Larson RA, van Besien K. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2005 May; 35(10):965-70. PMID: 15806131.
      Citations: 21     Fields:    Translation:Humans
    344. Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, Byrd JC. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol. 2005 May 20; 23(15):3404-11. PMID: 15824414.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    345. van Besien K, Artz A, Stock W. Unrelated donor transplantation over the age of 55. Are we merely getting (b)older? Leukemia. 2005 Jan; 19(1):31-3. PMID: 15526015.
      Citations: 7     Fields:    Translation:Humans
    346. Zimmerman TM, Harlin H, Odenike OM, Berk S, Sprague E, Karrison T, Stock W, Larson RA, Ratain MJ, Gajewski TF. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22. PMID: 15570084.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    347. Van Besien K, Mehra R, Wadehra N, Stock W, Khouri I, Giralt S, Devine S, Wickrema A, Peace D, Sosman J, Gajewski J, Champlin R. Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2004 Jun; 10(6):386-94. PMID: 15148492.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    348. Van Besien K, Smith S, Anastasi J, Larson R, Thirman M, Odenike T, Stock W. Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood. 2004 Jun 01; 103(11):4373-4. PMID: 15155474.
      Citations: 2     Fields:    Translation:HumansCells
    349. Marcucci G, Stock W, Dai G, Klisovic MI, Maharry K, Shen T, Liu S, Sher DA, Lucas D, Zwiebel A, Larson RA, Caligiuri MA, Bloomfield CD, Chan KK, Grever MR, Byrd JC. G3139, a BCL-2 antisense oligo-nucleotide, in AML. Ann Hematol. 2004; 83 Suppl 1:S93-4. PMID: 15124691.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    350. Van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, Maynard V, Stock W, Peace D, Ravandi F, Chen YH, Hoffman R, Sossman J. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Sep; 32(5):471-6. PMID: 12942092.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    351. van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, Maynard V, Stock W, Peace D, Ravandi F, Chen YH, Cheung T, Vijayakumar S, Hoffman R, Sosman J. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Jul; 32(1):9-13. PMID: 12815472.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    352. Verma A, Devine S, Morrow M, Chen YH, Mihalov M, Peace D, Stock W, Pursell K, Wickrema A, Yassine M, Jessop E, van Besien K. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. Bone Marrow Transplant. 2003 May; 31(9):813-6. PMID: 12732890.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    353. Stock W. Minimal residual disease: current status in leukemia. Clin Adv Hematol Oncol. 2003 Apr; 1(4):210-1. PMID: 16224407.
      Citations:    Fields:    Translation:Humans
    354. Silver RT, Peterson BL, Szatrowski TP, Powell BL, Stock W, Carroll AJ, Bloomfield CD, Schiffer CA, Larson RA. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. Leuk Lymphoma. 2003 Jan; 44(1):39-48. PMID: 12691141.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    355. Mata-Greenwood E, Cuendet M, Sher D, Gustin D, Stock W, Pezzuto JM. Brusatol-mediated induction of leukemic cell differentiation and G(1) arrest is associated with down-regulation of c-myc. Leukemia. 2002 Nov; 16(11):2275-84. PMID: 12399973.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    356. Verma A, Stock W, Lait M, Ferrer K, Quinn J, Platanias LC. Actinomycosis presenting as an oral ulcer in a neutropenic patient. South Med J. 2002 Sep; 95(9):1105. PMID: 12356125.
      Citations: 2     Fields:    Translation:Humans
    357. Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W, Maynard V, Jessop E, Peace D, Huml M, Thomason D, Chen YH, van Besien K. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002 Mar 15; 99(6):2255-8. PMID: 11877308.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    358. Verma A, Stock W, Norohna S, Shah R, Bradlow B, Platanias LC. Progressive transformation of germinal centers. Report of 2 cases and review of the literature. Acta Haematol. 2002; 108(1):33-8. PMID: 12145465.
      Citations: 2     Fields:    Translation:HumansCells
    359. Bartholomew A, Sher D, Sosler S, Stock W, Lazda V, Koshy M, Devine S, vanBesien K. Stem cell transplantation eliminates alloantibody in a highly sensitized patient. Transplantation. 2001 Nov 27; 72(10):1653-5. PMID: 11726826.
      Citations: 4     Fields:    Translation:Humans
    360. van Besien K, Keralavarma B, Devine S, Stock W. Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia. 2001 Sep; 15(9):1317-25. PMID: 11516091.
      Citations: 6     Fields:    Translation:Humans
    361. Devine SM, Sanborn R, Jessop E, Stock W, Huml M, Peace D, Wickrema A, Yassine M, Amin K, Thomason D, Chen YH, Devine H, Maningo M, van Besien K. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Bone Marrow Transplant. 2001 Sep; 28(6):557-62. PMID: 11607768.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    362. Hu YJ, Korotkov KV, Mehta R, Hatfield DL, Rotimi CN, Luke A, Prewitt TE, Cooper RS, Stock W, Vokes EE, Dolan ME, Gladyshev VN, Diamond AM. Distribution and functional consequences of nucleotide polymorphisms in the 3'-untranslated region of the human Sep15 gene. Cancer Res. 2001 Mar 01; 61(5):2307-10. PMID: 11280803.
      Citations: 50     Fields:    Translation:Humans
    363. Devine SM, Bartholomew AM, Mahmud N, Nelson M, Patil S, Hardy W, Sturgeon C, Hewett T, Chung T, Stock W, Sher D, Weissman S, Ferrer K, Mosca J, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol. 2001 Feb; 29(2):244-55. PMID: 11166464.
      Citations: 104     Fields:    Translation:AnimalsCells
    364. Sosman JA, Stiff P, Moss SM, Sorokin P, Martone B, Bayer R, van Besien K, Devine S, Stock W, Peace D, Chen Y, Long C, Gustin D, Viana M, Hoffman R. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. J Clin Oncol. 2001 Feb 01; 19(3):634-44. PMID: 11157013.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    365. Verma A, Stock W. Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach. Curr Opin Oncol. 2001 Jan; 13(1):14-20. PMID: 11148680.
      Citations: 4     Fields:    Translation:HumansCells
    366. Stock W, Estrov Z. Studies of minimal residual disease in acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1289-305, viii-ix. PMID: 11147224.
      Citations: 4     Fields:    Translation:Humans
    367. van Besien K, Bartholomew A, Stock W, Peace D, Devine S, Sher D, Sosman J, Chen YH, Koshy M, Hoffman R. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant. 2000 Aug; 26(4):445-9. PMID: 10982293.
      Citations: 24     Fields:    Translation:Humans
    368. Gudat P, Stock W, Pappert G, Grol M, Neumeier D, Luppa PB, Kaiser T. Biotinylated steroid derivatives as ligands for biospecific interaction analysis with monoclonal antibodies using immunosensor devices. Anal Biochem. 2000 Jul 01; 282(2):173-85. PMID: 10873271.
      Citations: 4     Fields:    Translation:Cells
    369. Fehniger TA, Bluman EM, Porter MM, Cooper MA, VanDeusen JB, Frankel SR, Stock W, Caligiuri MA, Mrózek E. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest. 2000 Jul; 106(1):117-24. PMID: 10880055; PMCID: PMC314354.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    370. Stock W, Hoffman R. White blood cells 1: non-malignant disorders. Lancet. 2000 Apr 15; 355(9212):1351-7. PMID: 10776761.
      Citations: 17     Fields:    Translation:Humans
    371. Stock W, Tsai T, Golden C, Rankin C, Sher D, Slovak ML, Pallavicini MG, Radich JP, Boldt DH. Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia. Blood. 2000 Apr 01; 95(7):2364-71. PMID: 10733508.
      Citations: 4     Fields:    Translation:Humans
    372. Usha L, Bradlow B, Stock W, Platanias LC. CD5+ immunophenotype in the bone marrow but not in the peripheral blood in a patient with hairy cell leukemia. Acta Haematol. 2000; 103(4):210-3. PMID: 11014896.
      Citations:    Fields:    Translation:HumansCells
    373. Wickrema A, Chen F, Namin F, Yi T, Ahmad S, Uddin S, Chen YH, Feldman L, Stock W, Hoffman R, Platanias LC. Defective expression of the SHP-1 phosphatase in polycythemia vera. Exp Hematol. 1999 Jul; 27(7):1124-32. PMID: 10390187.
      Citations: 5     Fields:    Translation:HumansCells
    374. Nand S, Stock W, Stiff P, Sosman J, Martone B, Radvany R. A phase II trial of interleukin-2 in myelodysplastic syndromes. Br J Haematol. 1998 Apr; 101(1):205-7. PMID: 9576203.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    375. Graupe F, Stock W, Hansen O. [Prognostic factors in perforating diverticulitis of the large intestine]. Chirurg. 1998 Apr; 69(4):443-9. PMID: 9612631.
      Citations: 24     Fields:    Translation:Humans
    376. Hansen O, Stock W, Graupe F. [Value of individually risk-adjusted after-care--economic management of oncologic effectiveness?]. Langenbecks Arch Chir Suppl Kongressbd. 1997; 114:665-8. PMID: 9574235.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    377. Felix R, Stock W, Mäurer J. [Characteristics of normal cross-sectional anatomy of the skin in high resolution magnetic resonance tomography]. Hautarzt. 1997 Jan; 48(1):26-30. PMID: 9132384.
      Citations: 1     Fields:    Translation:Humans
    378. Stock W, Westbrook CA, Peterson B, Arthur DC, Szatrowski TP, Silver RT, Sher DA, Wu D, Le Beau MM, Schiffer CA, Bloomfield CD. Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 1997 Jan; 15(1):26-36. PMID: 8996121.
      Citations: 1     Fields:    Translation:HumansCells
    379. Horrigan SK, Westbrook CA, Kim AH, Banerjee M, Stock W, Larson RA. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood. 1996 Oct 01; 88(7):2665-70. PMID: 8839861.
      Citations: 12     Fields:    Translation:HumansCells
    380. Schwenk W, Bracht B, Stock W, Graupe F, Kröner-Herwig B. [Psychological stress on patients in tumor after-care after R0 resection of colorectal carcinomas]. Chirurg. 1996 Jun; 67(6):604-9; discussion 609-10. PMID: 8767088.
      Citations: 3     Fields:    Translation:Humans
    381. Nand S, Stock W, Godwin J, Fisher SG. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol. 1996 May; 52(1):42-6. PMID: 8638610.
      Citations: 19     Fields:    Translation:Humans
    382. Zarras K, Graupe F, Dellana M, Stock W, Hansen O. [Surgical treatment of diverticulitis of the large intestine--a plea for early elective resection]. Zentralbl Chir. 1996; 121(3):190-200. PMID: 8867345.
      Citations: 2     Fields:    Translation:Humans
    383. Zarras K, Graupe F, Stock W, Hansen O. [Surgical therapy of sigmoid diverticulitis in elderly patients.--What decides against early elective resection]. Langenbecks Arch Chir Suppl Kongressbd. 1996; 113:470-3. PMID: 9101902.
      Citations:    Fields:    Translation:Humans
    384. Schwenk W, Mackrodt HG, Stock W, Graupe F. [Acceptance and effectiveness of surgical vascular consultation--is it worthwhile?]. Chirurg. 1995 Dec; 66(12):1239-44; discussion 1245-6. PMID: 8582169.
      Citations:    Fields:    Translation:Humans
    385. Sosman JA, Stiff PJ, Bayer RA, Peliska J, Peace DJ, Loutfi S, Stock W, Oldenburg D, Unverzagt K, Bender J, et al. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy. Bone Marrow Transplant. 1995 Nov; 16(5):655-61. PMID: 8547862.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    386. Lewan U, Dielert E, Helaly P, Stock W, Umbricht-Sprüngli RE. [Long-term outcome of the donor site after free, microvascular pedicled iliac crest transplantation: experiences with 95 cases]. Handchir Mikrochir Plast Chir. 1995 Sep; 27(5):233-41. PMID: 7498837.
      Citations:    Fields:    Translation:Humans
    387. Hucke HP, Graupe F, Stock W, Schwenk W. [Is the surgeon a prognostically relevant factor after R0-resection of colorectal carcinoma?]. Chirurg. 1995 Apr; 66(4):334-42; discussion 342-3. PMID: 7634944.
      Citations:    Fields:    Translation:Humans
    388. Joventino LP, Stock W, Lane NJ, Daly KM, Mick R, Le Beau MM, Larson RA. Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia. Leukemia. 1995 Mar; 9(3):433-9. PMID: 7885042.
      Citations: 1     Fields:    Translation:Humans
    389. Stock W, Thirman MJ, Dodge RK, Rowley JD, Diaz MO, Wurster-Hill D, Sobol RE, Davey FR, Larson RA, Westbrook CA, et al. Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study. Leukemia. 1994 Nov; 8(11):1918-22. PMID: 7967737.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    390. Eyssel M, Badke A, Hucke HP, Stock W, Schwenk W. [Risk analysis of primary endoprosthetic management of proximal femur fractures]. Unfallchirurgie. 1994 Aug; 20(4):216-22. PMID: 7941112.
      Citations: 3     Fields:    Translation:Humans
    391. Eyssel M, Badke A, Stock W, Schwenk W. [Results of management of pertrochanteric comminuted fractures in the elderly with a tumor shaft endoprostheses]. Aktuelle Traumatol. 1994 Feb; 24(1):6-11. PMID: 8165960.
      Citations: 1     Fields:    Translation:Humans
    392. Riggins GJ, Sherman SL, Phillips CN, Stock W, Westbrook CA, Warren ST. CGG-repeat polymorphism of the BCR gene rules out predisposing alleles leading to the Philadelphia chromosome. Genes Chromosomes Cancer. 1994 Feb; 9(2):141-4. PMID: 7513545.
      Citations: 2     Fields:    Translation:HumansCells
    393. Osswald J, Huppa C, Stock W, Schwenk W. [Results of regular follow-up after removal of colorectal adenomas]. Med Klin (Munich). 1993 Aug 15; 88(8):471-7. PMID: 8413048.
      Citations:    Fields:    Translation:Humans
    394. Le Beau MM, Espinosa R, Neuman WL, Stock W, Roulston D, Larson RA, Keinanen M, Westbrook CA. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci U S A. 1993 Jun 15; 90(12):5484-8. PMID: 8516290; PMCID: PMC46745.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    395. Spielberger RT, Stock W, Larson RA. Listeriosis after 2-chlorodeoxyadenosine treatment. N Engl J Med. 1993 Mar 18; 328(11):813-4. PMID: 8094890.
      Citations: 3     Fields:    Translation:Humans
    396. Schwenk W, Hucke HP, Stock W, Böhm B. Does methodic long-term follow-up affect survival after curative resection of colorectal carcinoma? Dis Colon Rectum. 1993 Mar; 36(3):280-6. PMID: 8449134.
      Citations: 30     Fields:    Translation:Humans
    397. Badke A, Zarras K, Stock W, Schwenk W, Böhm B. [Preoperative esophagogastroduodenoscopy before elective surgical therapy of symptomatic cholelithiasis]. Leber Magen Darm. 1992 Nov; 22(6):225-9. PMID: 1479867.
      Citations: 2     Fields:    Translation:Humans
    398. Hucke HP, Stock W, Graupe F, Böhm B. [Preoperative hemodilution before elective resections of colorectal cancers for sparing homologous blood transfusion]. Leber Magen Darm. 1992 May; 22(3):111-5. PMID: 1625508.
      Citations:    Fields:    Translation:Humans
    399. Hucke HP, Stock W, Schwenk W. [Postoperative complications of elective resection of the colon in diverticulitis]. Dtsch Med Wochenschr. 1992 Jan 10; 117(2):41-5. PMID: 1730200.
      Citations: 2     Fields:    Translation:Humans
    400. Schwenk W, Hucke HP, Stock W, Graupe F. [Inguinal hernia repair modified by Kirschner. A critical analysis after 11 years of clinical experience]. Langenbecks Arch Chir. 1992; 377(6):324-31. PMID: 1479855.
      Citations:    Fields:    Translation:Humans
    401. Stock W, Chandrasekharappa SC, Neuman WL, Le Beau MM, Brownstein BH, Westbrook CA. Characterization of yeast artificial chromosomes containing interleukin genes on human chromosome 5. Cytogenet Cell Genet. 1992; 61(4):263-5. PMID: 1486800.
      Citations: 2     Fields:    Translation:HumansCells
    402. Stock W, Lichtman S, Ratain MJ, O'Brein S, Vogelzang NJ, Van Echo DA. Response to high dose cyclophosphamide with GM-CSF in Merkel cell tumor. Ann Oncol. 1991 Jul; 2(7):522-3. PMID: 1911464.
      Citations:    Fields:    Translation:Humans
    403. Heimann PS, Vardiman JW, Stock W, Platanias LC, Golomb HM. CD5+, CD11c+, CD20+ hairy cell leukemia. Blood. 1991 Apr 01; 77(7):1617-9. PMID: 1706957.
      Citations: 1     Fields:    Translation:Humans
    404. Osswald J, Stock W, Böhm B. [Follow-up in stomach carcinoma]. Leber Magen Darm. 1991 Mar; 21(2):68, 71-4. PMID: 1645429.
      Citations: 1     Fields:    Translation:Humans
    405. Osswald J, Hucke HP, Stock W, Böhm B. [Individual risk-related after-care in colorectal cancer?]. Langenbecks Arch Chir. 1991; 376(6):314-22. PMID: 1723133.
      Citations: 1     Fields:    Translation:Humans
    406. Nouchirvani K, Hucke HP, Stock W, Böhm B. [Morbidity and mortality after elective resections of colorectal cancers]. Langenbecks Arch Chir. 1991; 376(2):93-101. PMID: 2056845.
      Citations: 1     Fields:    Translation:Humans
    407. Stock W, Larson RA. Neurocysticercosis Coincident with Acute Myeloid Leukemia: A Case Report. Leuk Lymphoma. 1991; 4(2):145-8. PMID: 27462945.
      Citations:    Fields:    
    408. Stock W, Dresing K. Ultrasonic endoluminal examination in the follow-up of colorectal cancer. Initial experience and results. Int J Colorectal Dis. 1990 Dec; 5(4):188-94. PMID: 2286800.
      Citations: 1     Fields:    Translation:Humans
    409. Nouchirvani K, Hucke HP, Stock W, Böhm B. [The effect of age and sex on localization, tumor stage and prognosis of colorectal carcinoma]. Med Klin (Munich). 1990 Oct 15; 85(10):586-90. PMID: 2233589.
      Citations: 1     Fields:    Translation:Humans
    410. Thomas JA, Stock WA. The concept of happiness: a multidimensional scaling investigation. Int J Aging Hum Dev. 1988; 27(2):141-54. PMID: 3246451.
      Citations:    Fields:    Translation:Humans
    411. Richter-Turtur M, Stock W, Wilker D, Geissler K, Schweiberer L. [Surgical treatment of large thoracic wall recurrences in breast cancer]. Chirurg. 1987 Sep; 58(9):607-11. PMID: 3677893.
      Citations:    Fields:    Translation:Humans
    412. Rassek D, Straub D, Sons HU, Stock W. [Results of the surgical treatment of gallbladder carcinomas]. Chirurg. 1985 Jul; 56(7):440-4. PMID: 4042758.
      Citations:    Fields:    Translation:Humans
    413. Stock W, Nitzschke E, Mackrodt HG. [Rational EDP-basic documentation in the surgical clinic]. Chirurg. 1982 Mar; 53(3):176-83. PMID: 7067540.
      Citations:    Fields:    Translation:Humans
    414. Ingianni G, Biemer E, Stock W. [Reimplantation of peripheral parts of the extremities. 808 cases and functional results]. Minerva Chir. 1981 Oct 31; 36(20):1337-44. PMID: 6117812.
      Citations:    Fields:    Translation:Humans
    Stock's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (927)
    Explore
    _
    Co-Authors (94)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _